1Statistical Analysis Plan
Study Code D3251C00003
Edition Number 3.0
Date 23 April 2018
A Randomised, Double-blind, Chronic Dosing (56 week) Placebo-
controlled, Parallel Group, Multicenter, Phase III Study to Evaluate the 
Efficacy and Safety of 2 Doses of Benralizumab (MEDI-563) in Patients 
with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (GALATHEA)
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.[ADDRESS_745953] OF ABBREVIATIONS .............................................................................. 8
AMENDMENT HI STORY................................................................................ 11
1. STUDY DETAILS ............................................................................................. 15
1.1 Study objectives................................................................................................. 15
1.1.1 Primary Objective .............................................................................................. 15
1.1.2 Secondary Objectiv es......................................................................................... 15
1.1.3 Safety Objective................................................................................................. 16
1.1.4 Exploratory  Objectives....................................................................................... 17
1.2 Study design ...................................................................................................... 17
1.3 Number of subjects ............................................................................................ 18
2. ANALYSIS SETS ............................................................................................. 19
2.1 Definition of analysis sets .................................................................................. 19
2.1.1 All patients analysis set...................................................................................... 19
2.1.2 Full analy sis set.................................................................................................. 20
2.1.3 Safety analysis set .............................................................................................. 20
2.1.4 Pharmacokinetic analysis set.............................................................................. 20
2.1.5 Sub-study an alysis set ........................................................................................ 20
2.2 Violations and deviations ................................................................................... 20
2.2.1 Important protocol  deviations............................................................................. 20
2.2.2 Visit window definiti ons .................................................................................... 21
2.2.3 The definition  of baseline................................................................................... 24
2.2.4 Prior/concomit ant medi catio ns ........................................................................... [ADDRESS_745954] COPD exacerbation (days) ............................................................. 27
3.2.2 Proportion of patients with @1 COPD exacerbation during 56 weeks of 
treatment............................................................................................................ 27
3.2.3 Annual rate of COPD exacerbations that are associated with an emergency 
room visit or a hospi[INVESTIGATOR_059] ............................................................................ 28
3.2.4 FEV 1 (L) pre-bronchodilator measure d at the study cen ter.................................. [ADDRESS_745955]. George’s Respi[INVESTIGATOR_21606] (SGRQ)................................................ [ADDRESS_745956] (CA T) .......................................................................... 30
3.3.3 Baseline/Transitional Dyspnea Index (BDI/TDI) ................................................ 30
3.3.4 Exacerbations of Chronic Pulmonary Disease Tool – Patient-reported 
Outcome (EXACT-PRO) ................................................................................... 31
3.3.5 Evaluating Respi[INVESTIGATOR_568923] (E-RS: COPD) ...................................................................................... 31
3.3.6 Total rescue medicati on use ............................................................................... 32
3.3.7 Nights with awakening due to respi[INVESTIGATOR_1856].......................................... 33
3.3.8 European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L)........................... 33
3.3.9 Clinician Global Impression of Change (CGIC) and Patient Global 
Impression of Change (PGIC) ............................................................................ [ADDRESS_745957] (6MWT)............................................................................. 34
3.4.2 Lung volumes .................................................................................................... 34
3.4.3 Di ffusion capacity of the l ung for carbon monoxide (DL CO)............................... 34
3.4.4 Sputum biomarkers / sputum cell c ount .............................................................. 35
3.5 Safety outcome variables.................................................................................... 35
3.5.1 Adverse events................................................................................................... 35
3.5.2 Laboratory variables .......................................................................................... 36
3.5.3 Twelve-lead el ectroca rdiogra m .......................................................................... 37
3.5.4 Physical examination ......................................................................................... 37
3.5.5 Vital signs .......................................................................................................... 37
3.6 Pharmacokinetic variables.................................................................................. 38
3.7 Immunogenicity variables .................................................................................. 38
4. ANALYSIS ME THODS .................................................................................... 38
4.1 General principles .............................................................................................. 38
4.1.1 Testing strategy to account for multiplicity considerations ................................. 39
4.2 Analysis  methods ............................................................................................... 41
4.2.1 Patient di sposition.............................................................................................. 41
4.2.2 Demography data and p atient characteristics ...................................................... 42
4.2.3 Prior and conco mitant med icatio ns..................................................................... 42
4.2.4 Study treatmen t adminis tratio n........................................................................... 42
4.2.5 Primary outcome  variable .................................................................................. 43
[IP_ADDRESS] Primary an alysi s................................................................................................. 43
[IP_ADDRESS] Subgroup analysis for the pr imary outcome variab le .......................................... 45
[IP_ADDRESS] Supportive analysis for the primary outcome variable ........................................ 45
4.2.6 Secondary efficacy outcome va riables................................................................ 46
[IP_ADDRESS] Proportion of subjects with @1 COPD exacerbation ............................................ 46
[IP_ADDRESS] Time to first COPD exacerbation ....................................................................... 46
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
[IP_ADDRESS] FEV 1(L) pre-bronchodilator measure d at the st udy centr e ................................. 47
[IP_ADDRESS] St. George’s Respi[INVESTIGATOR_21606] (SGRQ)................................................ 48
[IP_ADDRESS] COPD assessment tool (CAT) ............................................................................ 49
[IP_ADDRESS] Baseline/Transitional Dyspnea Index (BDI/TDI) ................................................ 49
[IP_ADDRESS] Exacerbations of Chronic Pulmonary Disease Tool – Patient-re ported 
Outcome (EXACT-PRO) ................................................................................... 50
[IP_ADDRESS] Evaluating Respi[INVESTIGATOR_568923] (E-RS: COPD) ...................................................................................... 50
[IP_ADDRESS] Medicat ion Use.................................................................................................. 50
[IP_ADDRESS] Nights with awakening due to respi[INVESTIGATOR_23908].......................................... 51
[IP_ADDRESS] Healthcare re source u tilization ........................................................................... 51
4.2.7 Additional modelling for primary and key seconda ry endpo ints ......................... 51
4.2.8 Exploratory  Objectives....................................................................................... 52
[IP_ADDRESS] European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) ........................... 52
[IP_ADDRESS] Clinician Global Impression of Change (CGIC) and Patient Global 
Impression of Change (PGIC) ............................................................................ 52
[IP_ADDRESS] Blood eosi nophil s............................................................................................... 52
[IP_ADDRESS] Serum bi omarkers .............................................................................................. 52
[IP_ADDRESS] Pharmacogenetics – DNA Sampling ................................................................... 53
[IP_ADDRESS] Mortality rate ..................................................................................................... 53
[IP_ADDRESS] Exploratory objectives in  a subset of sub jects ..................................................... 53
[IP_ADDRESS] Sputum biomarkers and differential cell c ounts .................................................. 54
4.2.9 Safety outco me variables.................................................................................... 55
[IP_ADDRESS] Adverse even ts (AEs)......................................................................................... 55
[IP_ADDRESS] Laboratory  data.................................................................................................. 56
[IP_ADDRESS] EC Gs ................................................................................................................. 57
[IP_ADDRESS] Physical examination ......................................................................................... 57
[IP_ADDRESS] Vital signs.......................................................................................................... 57
4.2.10 Pharmacokinetic analyses ................................................................................... 57
4.2.11 Immunogenicity analyses ................................................................................... 57
5. INTERIM ANALYSES ..................................................................................... 58
6. CHANGES OF ANALYSIS FROM PROTOCOL ............................................. 58
7. REFERENCES .................................................................................................. 59
8. APPENDIX ....................................................................................................... 62
8.1 Accounting for missing data ............................................................................... 62
8.2 Partial dates for adverse events and prior/concomitant medication ..................... [ADDRESS_745958] Aspartate aminotransferase
AZDD [COMPANY_008] drug dictionaryBD Bronchodilator
BDI/TDI Baseline/transitional dyspnea index
BMI Body Mass IndexBODE Body-mass index, airflow obstruction, dyspnea, and exercise capacity indexCAT COPD assessment tool
CGIC Clinical global impression of change
CI Confidence intervalCMH Cochran–Mantel–Haenszel
COPD Chronic obstructive pulmonary disease
COTE COPD specific comorbidity testCSP Clinical study protocol
CSR Clinical study report
DAE Discontinuation of investigational product due to adverse eventDBP Diastolic blood pressureDL
CO Diffusion capacity of carbon monoxide
DNA Deoxyribonucleic acid 
ECG Electrocardiogram
ECL Electrochemiluminescent 
eCRF Electronic case report form
eDiary Electronic diaryEOT End of treatmentEQ-5D-5L European quality of life-5 dimensions-5 levels
ePRO Electronic patient reported outcome
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
9Abbreviation or 
special termExplanation
ER Emergency room
E-RS: COPD Evaluating respi[INVESTIGATOR_568924]-PRO Exacerbations of chronic pulmonary disease tool – Patient-reported 
outcome
FAS Full analysis set 
FEV 1 Forced expi[INVESTIGATOR_3741] 1 second
FRC Functional residual capacityFU Follow-up (visit)
FWER Family-wise error rate
GCP Good clinical practiceGGT Gamma-glutamyltransferase
GOLD Global Initiative for Chronic Obstructive Lung Disease
IC Inspi[INVESTIGATOR_568925]-[ADDRESS_745959] model for repeated measuresN/A Not applicablenAb Neutralizing antibodies
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.[ADDRESS_745960]. George’s respi[INVESTIGATOR_568926] (units)SOC System organ classTBL Total bilirubin
TLC Total lung capacity
ULN Upper limit of normal[LOCATION_006] [LOCATION_008]
US [LOCATION_002]
WBDC Web based data capture
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
11AMENDMENT HISTORY
Date Brief description of change
14 December 2015
(v2.0)!SAP text amendment due to CSP amendment 4.0: lowering baseline 
eosinophil cutoff from @300/KL to @220/KL, corresponding sample size 
changes, and additional covariate of baseline eosinophil cohort (220-299/ KL 
or @300/KL) for @220/KL inferential analyses.
!Clarification around the process for identifying and summarizing important 
protocol deviations.
!Updates to visit window definitions, taking into account the way in which 
daily diary metrics are recorded (daytime assessments recorded in the evening and night-time assessments recorded the morning of following calendar day) and ensuring that there are no gaps in visit windows. Update 
to definition of study day; relative to randomization to align with the way in 
which study visits are scheduled.
!Clarification provided on the definition of baseline for efficacy versus safety 
endpoints.
!Clarification on the definition of prior and concomitant medications.
!Clarification provided on summaries of baseline demographic data and 
patient characteristics by [CONTACT_568974] (<220/ KL, 220/KL).
!Updated the method for primary endpoint from patient-based approach to 
time-based approach.
!Additional details added for the definition of maximum follow-up time for 
exacerbations and added sensitivity analysis for on-treatment analysis, multiple imputation method details, and additional statistical modelling (primary and key secondary endpoints).
!Updated the method for subgroup analyses (primary and key secondary 
endpoints) to a single model per subgroup factor with inclusion of subgroup main effect and treatment*subgroup interaction, to align with methods 
described in the protocol.
!Updates to expand the list of endpoints to be analysed in patients with 
baseline blood eosinophil count <220/ KL; and also by [CONTACT_568975] (<150/ KL, 150-219/ KL, 220-299/ KL, 300-
449/KL, @450/ KL), and cumulative baseline blood eosinophil count 
categories ( @150/KL, @200/KL, @250/KL, @300/KL, @350/KL, @400/KL, 
@450/
KL).
!Clarification provided on SGRQ total score response status and analysis 
method.
!Analysis of SGRQ and TDI responders updated to evaluate patients with 
missing data at Week 56 as non-responders.
!Clarification on the definition of an EXACT-PRO event, and rescue 
medication (incorporating morning/evening assessments).
!Removal of ANCOVA analysis for E-RS: COPD total score.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
12Date Brief description of change
!Updated analysis of healthcare utilization from annual rates to summary 
statistics.
!Added descriptions and statistical summary analyses on exploratory 
endpoints for subset analysis. 
!Updated categorization of adverse events into study periods (on-study, on-
treatment, and post-treatment) and clarification of adverse event summaries 
above/below 220/ KL. 
!Updates to incorporate protocol amendments, including: addition of CGIC 
and PGIC endpoints, removal of ADA analysis set (as analyses of ADA will 
be conducted in the safety set), removal of analysis of potential risks 
(included as part of adverse events).
!Clarifications on sputum biomarkers / cell count reported separately in a 
scientific report or publication.
!Added immunogenicity analyses and reference to the separate Statistical 
Analysis Plan for Benralizumab Anti-Drug Antibody data.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
13Date Brief description of change
23 April 2018 
(v3.0)!Removed text on 10% drop out rate in sample size calculation erroneously 
included in the CSP. Actual sample sizes in CSP and SAP are correct and do 
not account for a 10% drop out rate. 
!Added definition for sub-study analysis set
!Clarified ePRO data will be analyzed up to completion or discontinuation 
date and exclude data after ICF withdrawal
!Updated baseline definition for EQ-5D-5L
!Clarified baseline eosinophil levels for stratification are taken from central 
laboratory. Only if lab data is missing will IVRS stratification be used. 
!Added imputation rules for partially missing systemic corticosteroid or 
antibiotic exacerbation start/end dates
!Added summary of healthcare resource utilization annual rates
!Adding missing data rules for SGRQ and CAT scores
!Changed nights with awakenings due to COPD to due to respi[INVESTIGATOR_037], and removed analysis of nights with awakenings requiring 
rescue medication to align with actual ePRO setup
!Updated AE definitions for on-study, on-treatment, and post-treatment 
periods
!Added imputation rules for inferential analyses in case of missing 
background therapy 
!Added details of disposition summary
!Added marginal standardization method for analyzing negative binomial 
models
!Added weights will be used for analysis by [CONTACT_568976]
!Added supportive/sensitivity analyses to the primary endpoint: 
exacerbations associated with hospi[INVESTIGATOR_30059], exacerbations with data truncated at the point when subjects switched background therapi[INVESTIGATOR_014], 
exacerbations 
!Added subgroup analyses to the primary endpoint: by [CONTACT_568977], 
smoking status
!Added subgroup analyses for pre-BD FEV
1: baseline eosinophil categories, 
cumulative eosinophil categories, and prior exacerbations
!Added rules for MMRM covariance structures when convergence issues 
arise
!Added subgroup analyses for SGRQ: baseline eosinophil categories and  
cumulative eosinophil categories
!Added sensitivity analysis for SGRQ responder analysis using LOCF
!Added summaries for switches in background therapy during the study
!Added sensitivity analyses for primary and key secondary endpoints 
excluding potential data anomalies
!Added plot comparing historical versus baseline eosinophil levels
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
14Date Brief description of change
!Added sub-study sputum analyses
!Changed cutoff for most common AEs from @5% to @3%
!Added summaries of injection site reaction AEs
!Added summaries of hypersensitivity AEs causally related with IP
!Added SAE narratives will be provided
!Added final list of important protocol deviations in appendix
!Added all ADA analyses in appendix
!Removed pDRMI from all MI analyses and MAR from on-treatment MI 
analyses
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
151. STUDY DETAILS
This statistical analysis plan (SAP) outlines the analyses to be generated for the global clinical 
study report (CSR). Additional analyses required for regional submissions will be pre-
specified in a separate analysis plan and will be submitted to the appropriate authorities.
1.1 Study objectives
1.1.1 Primary Objective
Primary Objective: Outcome Measure:
To evaluate the effect of 2 doses of
benralizumab on COPD exacerbations in subjects with moderate to very severe COPDAnnual COPD exacerbation rate, where a COPD 
exacerbation is defined by [CONTACT_568978]:
!Use of systemic corticosteroids for at least 3 
days; a single depot injectable dose of corticosteroids will be considered equivalent to a 
3-day course of systemic corticosteroids; and/or
!Use of antibiotics; and/or
!An inpatient hospi[INVESTIGATOR_568927]
1.1.2 Secondary Objectives
Secondary Objective: Outcome Measure:
To evaluate the effect of 2 doses of benralizumab 
on health status/ health-related quality of life!St. George’s Respi[INVESTIGATOR_6015] 
(SGRQ) *
!COPD assessment tool (CAT)
To evaluate the effect of 2 doses of benralizumab 
on pulmonary functionPre-dose/pre-bronchodilator Forced Expi[INVESTIGATOR_568928] 1 second (FEV 1)*at the study center
To evaluate the effect of 2 doses of benralizumab 
on respi[INVESTIGATOR_1856]!Baseline/Transitional Dyspnea Index 
(BDI/TDI)
!Evaluating Respi[INVESTIGATOR_568929] (E-RS: COPD)
To evaluate the effect of 2 doses of benralizumab 
on rescue medication useTotal rescue medication use (average puffs/day)
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
16Secondary Objective: Outcome Measure:
To evaluate the effect of [ADDRESS_745961]-PRO defined events.Exacerbations of Chronic Pulmonary Disease 
Tool – Patient-reported Outcome (EXACT-PRO)
To evaluate the effect of [ADDRESS_745962] COPD exacerbation and proportion 
of subjects with @[ADDRESS_745963] of 2 doses of benralizumab 
on healthcare resource utilization due to COPDAnnual rate of hospi[INVESTIGATOR_568930]; 
annual rate of hospi[INVESTIGATOR_568931]; annual rate of unscheduled outpatient visits including 
unscheduled visits to study centers due to COPD; 
and annual rate of unscheduled healthcare 
encounters due to COPD
To evaluate the pharmacokinetics and 
immunogenicity of 2 doses of benralizumab!Pharmacokinetic (PK) parameters
!Anti-drug antibodies (ADA)
* Key secondary efficacy endpoints (multiplicity protected endpoints in patients with baseline blood eosinophil 
counts @220/KL).
A summary of PK analysis results will be reported either in the Clinical Study Report (CSR) 
itself or as an addendum to the CSR.
1.1.3 Safety Objective
Safety Objective: Outcome Measure:
To evaluate the safety and tolerability of 2 doses 
of benralizumab!Adverse events/ Serious adverse events 
(AE/SAE)
!Laboratory variables
!12 lead Electrocardiogram (ECG)
!Physical Examination
!Vital Signs
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
171.1.4 Exploratory Objectives
Exploratory Objective: Outcome Measure:
To evaluate the effect of 2 doses of benralizumab 
on general health statusEuropean Quality of Life-5 Dimensions-5 Levels
(EQ-5D-5L)
To evaluate the impact of [ADDRESS_745964] and store DNA for exploratory research 
into genes/genetic variation that may influence 
response (ie, distribution, safety, tolerability and 
efficacy) to benralizumabPharmacogenetic sample (see CSP Appendix D)
To evaluate the effect of 2 doses of benralizumab 
on patient and physician global assessmentsPatient Global Impression of Change (PGIC) and 
Clinical Global Impression of Change (CGIC)
To evaluate the effect of [ADDRESS_745965] Bronchodilator (BD) FEV [ADDRESS_745966] of 2 doses of benralizumab 
on lung volumes in a subset of subjectsInspi[INVESTIGATOR_10226] (IC), Total Lung Capacity 
(TLC), Residual Volume (RV)
To evaluate the effect of 2 doses of benralizumab on DL
COin a subset of subjectsDiffusion of carbon monoxide capacity (DLCO)
To evaluate the effect of [ADDRESS_745967] (6MWT)
To evaluate the effect of 2 doses of benralizumab 
on sputum biomarkers/cell counts and 
microbiology in a subset of subjects!Sputum biomarkers
!Sputum cell counts and differential, 
microbiome
The results of the exploratory objectives may be reported outside of the CSR.
1.2 Study design
This is a randomised, double-blind, placebo-controlled, parallel group, multicentre, phase III 
study to evaluate the efficacy and safe ty of benralizumab (MEDI-563), 30mg and 100mg 
doses administered by [CONTACT_6567] (SC) injection every [ADDRESS_745968] maintenance therapy (inhaled corticosteroid/long-acting P2 agonist 
(ICS/LABA), long-acting P2 agonist /long acting muscarinic antagonist (LABA/LAMA) or 
ICS/LABA/LAMA) with a history of COPD exacerbation(s) in the year prior to enrolment
(Week -4).
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
18The study will recruit approximately 1626 subjec ts randomised 1:1:1 to the treatment arms 
stratified by [CONTACT_568979] ( @300/KL or <300/ KL). Subjects will be 
recruited based on baseline blood eosinophil counts <220/ KL, 220-299/ KL, and @300/KL. The 
approximately 2:1 ratio between @220/KL and <220/ KL allows analysis of the primary 
population for subjects most likely to respond to benralizumab (i.e., @220/KL), while still 
including subjects below this threshold in order to help understand efficacy and safety in this 
group. The subject recruitment will also be cappe d at the study level for the cohorts with 
baseline eosinophil count (<220/ KL, 220-299/ KL, or @300/KL) in order to keep predefined 
cohort sample size and approximately 2:1 ratio of subjects above and below the boundary of 
220/KL. Instructions for screen failing these subjects  from the study after a stratum is closed 
are noted in the protocol (Section 4.1.3 of the protocol). The estimated number of recruited 
subjects per arm in each of these cohorts (<220/ QL, 220-299/ QL, @300/QL) will be 174, 90, 
and 278, respectively.
Approximately 10% -15% of subjects (54-81 subjects in each arm of the study) will be 
included in a study subset that includes advanced induced sputum analysis and advanced 
pulmonary function testing. The aim of the subset analysis is to further explore the role of eosinophils in COPD and the effect of benralizumab on sputum and pulmonary physiology. 
Additional analysis on exercise endurance will also be performed on this subset of subjects 
using the [ADDRESS_745969] (IP) will be administered at the study centre every [ADDRESS_745970] treatment evaluation will be performed at Week 56.
After the initial enrolment and confirmation of the entry criteria, subjects will proceed to the 
screening/run-in period for [ADDRESS_745971] dose of be nralizumab/placebo administered at Week 48. The 
end of treatment (EOT) visit will occur at Week 56. Subjects will be maintained on their currently prescribed maintenance therapi[INVESTIGATOR_014], from enrolment throughout the run-in and 
treatment period.
Final follow-up visit will be conducted at Week 60. See CSP Section 4, Tables [ADDRESS_745972] of visits and assessments.
1.3 Number of subjects
The study will recruit subjects with blood eosinophil counts @220/KL and <220/ KL at a ratio of 
approximately 2:1 and the study is powered for the primary efficacy analysis of the subjects 
with baseline blood eosinophils @220/KL. For the primary endpoint annual COPD 
exacerbation rate, 348 subjects with baseline blood eosinophil counts @220/KL per treatment 
arm (1044 total) will need to be randomised to achieve 90% power of detecting a 30% reduction in both benralizumab dose groups versus placebo after multiplicity adjustment. This 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
19calculation has assumed 2-sided 4% alpha level test, an annual placebo rate of 0.93 
events/subject (1.0 events/subject/56 weeks), and a negative binomial shape parameter of 0.4. 
The sample size calculation is based on simulations and has accounted for the power loss from 
a proposed fut ility analysis. Acc ording to the approximately 2:1 ratio, the study will also enrol
174 subjects/arm (522 total) with baseline blood eosinophil counts <220/ KL. An additional 20 
subjects/arm will also be recruited to the 220-299/ QL cohort to better characterize patients 
within this cohort. This addition results in an overall 368 subjects/arm in the @220/KL cohort 
(1104 total). Therefore, a total of 1626 subjects are expected to be randomised in the study.
A futility analysis based on the pr imary endpoint will be conducted in this study. The fut ility 
analysis will be carried out using pre-defin ed rules by [CONTACT_568980] (IDMC) in order to ensure the integrity of the blinded nature of the 
study. An IDMC charter and analysis plan will be created to detail the data to be reviewed, 
along with the roles and responsibilities of the IDMC members.  
The sample size necessary to achieve a stated power (90% in our case) in this study is 
calculated based on the estimate of overall exacerbation rate and shape parameter from the 
negative binomial model. In order to better estimate the overall exacerbation rate and shape parameter, a blinded sample size re-estimation will be conducted before the last subject with 
baseline eosinophil counts @220/KL is randomised. The sample size re-estimation will use 
blinded estimates of the overall exacerbation rate as well as the shape parameter from data pooled across all benralizumab doses and placebo for subjects with eosinophil counts @220/KL 
and the potential for >180 days of follow-up time, including prematurely withdrawn subjects. 
Strictly no treatment information will be used in the review. The exacerbation rate and shape parameter will be estimated using the maximum likelihood approach as proposed by [CONTACT_568981] 2010 . Since this review will be performed in a blinded fashion, no adjustment 
for the type I error is needed. Additional b linded review(s) will be conducted if deemed 
necessary by [CONTACT_456]. The blinding will be strictly maintained and not be affected by [CONTACT_387704](s) in any measure. Details of the sample size re-estimation is included in a separate 
blinded data review plan.
2. ANALYSIS SETS
2.1 Definition of analysis sets
Five patient populations are defined below: all patient analysis set, full analysis set (FAS; 
effectively the ITT population), safety analysis set, pharmacokinetics (PK) analysis set, and 
sub-study analysis set. Subjects must have provided their informed consent. If no signed informed consent is collected (major protocol deviation), then the subject will be excluded 
from all analysis sets defined below.
2.1.[ADDRESS_745973] will be classified as the higher active dose. All safety summaries and anti-drug antibodies (ADA) analyses will be based on this analysis set.
2.1.[ADDRESS_745974] dose will be included in the PK analysis set. All PK summaries will 
be based on this analysis set.
2.1.5 Sub-study analysis set
This analysis set comprises all subjects who participated in a sub-study that includes advanced 
induced sputum analysis and advanced pulmonary function testing. This sub-study was 
performed in approximately 10% -15% of subjects (54-81 subjects in each arm of the study) at 
a limited number of sites in the US, Canada and [LOCATION_006].
2.[ADDRESS_745975]
the completeness, accuracy, and/or reliability of the study data or that may significantly affect 
a subject’s rights, safety, or well-being.
The final list of important protocol deviations will be documented prior to unblinding the 
study data, and will include but is not limited to:
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
21! Eligibility criteria not met (patients incorrectly randomised) – deviations from 
inclusion criteria
! Eligibility criteria not met (patients incorrectly randomised) – deviations from 
exclusion criteria
! Deviations from IP discontinuation procedures
! Received prohibited/restricted concomitant medication
! Deviations from requirements on background double/triple COPD therapy
! Deviations from visit schedule and study procedures
! IP management and treatment unblinding
! Other (such deviations will be clearly described in the CSR)
Only important protocol deviations will be summarised and listed in the CSR. Important 
protocol deviations will be reviewed and documented by [CONTACT_568982]. Additional details are provided in Appendix 8.4.
Subjects for whom significant protocol deviations were recorded that impact the interpretation 
of the study safety outcomes will have a footnote added to applicable output to describe the 
deviation and its potential impact. Such subjects will be identified as part of the protocol 
deviation review process prior to database lock.
2.2.2 Visit window definitions
For the exacerbation-related analyses, no windo ws will be applied. For local laboratory and all 
vital signs, the visit recorded in web based data capture (WBDC) will be used. For endpoints 
that present visit-based data, the variables will be su mmarised based on the scheduled days 
with adjusted analysis-defined visit windows. The adjusted analysis-defined visit windows will be based on the collection schedule listed in the protocol and variables will be windowed 
to the closest scheduled visit for that variable. 
Visit windows have been constructed so that every observation collected can be allocated to a 
particular visit. No visit windows will be defined for screening visits.
The general adjusted analysis-defined visit windows for assessments are summarised in Table 
1.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
22Table 1 General analysis-defined visit windows for assessments
Analysis-Defined Windows Visit Scheduled Study Day Maximum Windows
Week 0 Day 1 1 Study Day=1 
Week X X*7+1=a 2 U Study Days U ((b-a)/2+a)-1
Week Y Y*7 +1=b ((b-a)/2+a) UStudy Days U((c-b)/2+b)-1
Week Z (Follow-up) Z*7+1=c ((c-b)/2+b) UStudy Days 
Study day will be defined as follows:
(Date of assessment – date of randomization) +1
For each analysis parameter, the windowing will be based on the protocol-specified schedule 
of events as defined in Section 4 of the protocol.
If multiple readings are recorded within a single visit window, please refer to the rules below. 
! If there are [ADDRESS_745976] to the scheduled visit will be used in the analysis. 
! If 2 observations are equidistant from the scheduled visit, then the non-missing 
observation with the earlier collection date will be used in the analysis. 
! If 2 observations are collected on the same day, then the non-missing 1 with the 
earlier collection time will be included in the analysis. 
For patient reported outcomes collected twice daily (i.e., rescue medication use), if 2
observations are collected on the same day during the same period (i.e., AM or PM) then the 
non-missing observation with the earlier collection time during the period will be included in the analysis.
If a visit window does not contain any observations, then the data will remain missing. 
For endpoints which are not collected every 4 weeks, such as EQ-5D-5L which is assessed 
every week, the above rules will be applied to derive adjusted analysis defined visit windows 
based on the protocol-defined visit schedule for that endpoint.
For pre-bronchodilator FEV
1(L), the non-missing value with acceptable quality (acceptable or 
borderline quality grade) which is closest to the scheduled visit will be included in the 
analysis.  For post-bronchodilator FEV 1assessed in the subset of subjects, the highest value 
with acceptable quality from the same date as the pre-bronchodilator FEV 1result will be used.
For the patient-report questionnaires co llected by [CONTACT_568983] 
(ePRO), the following rules will be applied:
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.[ADDRESS_745977] fall within specified AM/PM windows. Any observation recorded after the morning of Study Day [ADDRESS_745978] 14 days from evening of Study Day -14 to the morning of 
Study Day 1
Week 2 15Evening of Study Day 1 to the morning of Study Day 15
Week 4 29 Evening of Study Day 15 to the morning of Study Day 29
Week 6 43Evening of Study Day 29 to the morning of Study Day 43
Week 8 57 Evening of Study Day 43 to the morning of Study Day 57
Week 10 71Evening of Study Day 57 to the morning of Study Day 71
Week 12 85Evening of Study Day 71 to the morning of Study Day 85
Week 14 99Evening of Study Day 85 to the morning of Study Day 99
Week 16 113Evening of Study Day 99 to the morning of Study Day 113
Week 18 127Evening o fStudy Day 113 to the morning of Study Day 127
Week 20 141Evening of Study Day 127 to the morning of Study Day 141
Week 22 155Evening of Study Day 141 to the morning of Study Day 155
Week 24 169Evening of Study Day 155 to the morning of Study Day 169
Week 26 183Evening of Study Day 169 to the morning of Study Day 183
Week 28 197Evening of Study Day 183 to the morning of Study Day 197
Week 30 211Evening of Study Day 197 to the morning of Study Day 211
Week 32 225Evening of Study Day 211 to the morning of Study Day 225
Week 34 239Evening of Study Day 225 to the morning of Study Day 239
Week 36 253Evening of Study Day 239 to the morning of Study Day 253
Week 38 267Evening of Study Day 253 to the morning of Study Day 267
Week 40 281Evening of Study Day 267 to the morning of Study Day 281
Week 42 295Evening of Study Day 281 to the morning of Study Day 295
Week 44 309Evening of Study Day 295 to the morning of Study Day 309
Week 46 323Evening of Study Day 309 to the morning of Study Day 323
Week 48 337Evening of Study Day 323 to the morning of Study Day 337
Week 50 351 Evening of Study Day 337 to the morning of Study Day 351
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
24Week 52 365 Evening of Study Day 351 to the morning of Study Day 365
Week 54 379 Evening of Study Day 365 to the morning of Study Day 379
Week 56 393 Evening of Study Day 379 to the morning of Study Day 393
For overall analyses not based on any particular study visit, all data will be listed and/or 
analysed, including any repeat or unscheduled visits, unless otherwise specified. For safety 
endpoints, all post-baseline results will be included in the overall analysis up to and including 
the follow-up visit. For efficacy endpoints, the post-baseline treatment period will be included 
up to and including the end of treatment (EOT) visit (Visit 19, Week 56).
2.2.[ADDRESS_745979] dose of study treatment will serve as the baseline me asurement for safety e ndpoints. If there is no 
value prior to randomization (or the first dose of study treatment, depending on the endpoint), 
then the baseline value will not be imputed and will be set to missing. No data known to be collected post first dose will be used in determining the baseline value, unless otherwise 
specified.
For baseline respi[INVESTIGATOR_568932], the latest screening 
assessment will be used
.
For pre-bronchodilator FEV 1(L), the last non-missing value with acceptable quality 
(acceptable or borderline quality grade) on or prior to the date of randomization w ill be used 
as baseline. The first dose of study treatment is scheduled to be administered on the date of 
randomization (Visit 4), however if the first dose of study treatment is dela yed until after the 
date of randomization, the last recorded value wit h acceptable quality prior to first dose of 
study treatment will be used as baseline measurement for spi[INVESTIGATOR_328649]. 
Baseline EQ-5D-5L will be the Visit 4 assessment if available; Visit 3 assessment if Visit 4 
assessment is missing; or set to missing if bot h Visit [ADDRESS_745980] over the 7 
days prior to randomization. A minimum of 4 days of data (>50%) is required for calculating 
the baseline total score. To allow for improvement or deterioration in disease state over the 
course of the trial, the baseline total score will be reset every [ADDRESS_745981]-PRO defined event.
For E-RS: COPD, data collected in the last 14 days prior to randomization will be used to 
calculate the individual E-RS: COPD total and subscale baseline means. If more than 7 daily 
measures/scores (>50%) are missing, then baseline is set to missing.
For rescue medication use and nights with awaken ings due to respi[INVESTIGATOR_1856], baseline 
is defined as the mean from the last [ADDRESS_745982] udy Day -14 to the morning of Study Day 1.
The biweekly mean is calculated as the sum of all non-missing daily measures/scores over 14 
sequential days divided by [CONTACT_154562]-missing daily measures/scores. If more than 7 
daily measures/scores (>50%) within the baseline period are missing, then baseline is set to missing.
For summaries of laboratory results by [CONTACT_568984], 
the last non-missing assessment prior to first dose of study treatment will be used as baseline. For ECG, the last non-missing measurement at Week -1 (Visit 3) will be the baseline value.
For all data summaries and analyses by [CONTACT_568985] (<220/ QL vs. 
@220/QL), baseline blood eosinophil count category (<150/ KL, 150-219/ KL, 220-299/ KL, 300-
399/KL, @400/KL), baseline blood eosinophil count cumulative categories (<150/ KL,@150/KL, 
<220/KL,@220/KL, <300/KL, @300/KL, <400/KL, @400/KL) or continuous baseline blood 
eosinophil count (i.e., modeling activities), the blood eosinophil count result from the central laboratory will be used. If no data is available, then the stratum recorded in the IVRS system 
will be used to classify subjects into baseline blood eosinophil count strata (<220/ QL vs. 
@220/QL), while for patients in the @220/QL stratum, the IVRS data will be used to further 
classify subjects (220-299/ QL vs. @300/QL) for inferential analyses where this is included as a 
covariate in the model. The other baseline blood eosinophil count categories will be set to 
missing.
2.2.4 Prior/concomitant medications
Background COPD medication (i.e., double/triple therapy) will be classified as a ‘COPD 
medication at baseline’ if it started on or prior to randomization and was ongoing after 
randomization.
A medication will be regarded as ‘prior’ if it was stopped on or before the date of 
randomization (medication stop date U date of randomization).
A medication will be regarded as ‘concomitant’ if the start date is after the date of 
randomization, or if it started on or prior to th e date of randomization and was ongoing after 
the date of randomization.
3. PRIMARY AND SECONDARY VARIABLES
3.[ADDRESS_745983]’s baseline COPD symptoms that lasts 2 or more days, is beyond normal day-to-day va riation, is acute in onset and may warrant a 
change in regular medication, and leads to any of the following:
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
26! Use of systemic corticosteroids for at least 3 days; a single depot injectable dose of 
corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids 
! Use of antibiotics
! An inpatient hospi[INVESTIGATOR_568933].
Exacerbations will be considered moderate if they require treatment with systemic steroids 
and/or antibiotics, and do not result in hospi[INVESTIGATOR_30059]. Exacerbations will be 
considered severe if they result in hospi[INVESTIGATOR_30059].
In order to calculate the number of exacerbations experienced by a patient during the 56-week 
treatment period, the following rule will be applied:
The start of an exacerbation is defined as the start date of systemic corticosteroids or 
antibiotic treatment or hospi[INVESTIGATOR_063], whichever occurs earlier, and the end date is defined as the last day of systemic corticosteroids or antibiotic treatment or hospi[INVESTIGATOR_7954], whichever occurs later. The last date of depot corticosteroid injection will be 
calculated as the day of injection plus [ADDRESS_745984] dose of systemic steroids (oral, 
intramuscular (IM), intravenous (IV)), last dose of antibiotics, or hospi[INVESTIGATOR_568934] t. Inpatient hospi[INVESTIGATOR_568935] a new exacerbation. In order to be counted 
as a new exacerbation it must be preceded by [CONTACT_2669] 7 days in which none of the exacerbation 
criterion is fulfilled.
Maximum follow-up time for calculation of the annual exacerbation rate is approximately 56 
weeks, defined as the time from randomization up to and including the date of Visit 19 (EOT 
visit at Week 56). For patients who discontinue st udy treatment and remain in the study after 
the IPD visit, exacerbations will be coun ted from the time of ra ndomization up to and 
including the date of Visit 19 (Week 56). For a patient lost to follow-up before Visit 19 (Week 
56), the follow-up time will be defined as the time from randomization to the time point after 
which an exacerbation could not be assessed. Exacerbations that start after Visit 19 (Week 56)
will not be included in the efficacy assessments but will be listed. If a subject misses Visit 19 
(Week 56), then any exacerbations that start af ter the scheduled Visit 19 (Week 56) date (i.e.,
Study Day 393) will be excluded from efficacy  assessments. If an exacerbation is ongoing at 
Visit 19 (Week 56), the exacerbation will be counted in the calculation of annual exacerbation 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
27rate, however the maximum follow-up time will be truncated at the date of Visit 19 (Week 
56), as will the duration of the exacerbation. 
For the production of summary statistics, the annual exacerbation rate in each treatment group 
will be calculated using the time-based approach below:
Annual Exacerbation Rate = 365.25*Total Number of Exacerbations / Total duration of 
follow-up within the treatment group (days)
The on-treatment annual exacerbation rate will be calculated similarly, as a sensitivity 
analysis, using only exacerbations and follow-up occurring during the on-treatment period as 
defined in Section 3.5.[ADDRESS_745985] of out-of-window 
EOT visits on the annual exacerbation rate. For this analysis, the exacerbation follow up 
period will be truncated at Day 406 (according to the analysis visit windowing described in Section 2.2.2 for the EOT visit at Week 56). Exacerbations recorded with start date after Day 
[ADDRESS_745986] COPD exacerbation (days)
Time from randomization to the first COPD exacerbation will be used as a supportive variable 
to the primary outcome variable, and is calculated as follows:
Start Date of first COPD exacerbation WDate of Randomization + 1.
An exacerbation event will be defined in the same way as outlined in Section 3.1. The time to 
first COPD exacerbation for patients who do not experience a COPD exacerbation during the
treatment period will be censored at the date of their last visit for the 56-week double-blind 
treatment period, and for lost-to-follow-up patie nts, at the time point after which an 
exacerbation could not be assessed or at [ADDRESS_745987] COPD exacerbation associated with a hospi[INVESTIGATOR_568936].
3.2.2 Proportion of patients with @1 COPD exacerbation during 56 weeks of 
treatment
The proportion of patients with @ [ADDRESS_745988] as outlined in Section 3.1. In the 
statistical analysis, a binary variable taking on the value 1 if a patient has experienced 1 or 
more exacerbations during the 56-week double-blind treatment period and 0 otherwise, will be 
used as response variable.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
283.2.3 Annual rate of COPD exacerbations that are associated with an emergency 
room visit or a hospi[INVESTIGATOR_568937] (ER) 
visit or a hospi[INVESTIGATOR_479946] a secondary efficacy variable, based on data recorded in the 
eCRF. 
The number of COPD exacerbations associated with a hospi[INVESTIGATOR_568938] a patient during the 56-week treatment peri od and maximum follow-up time used in the 
calculation of this annual exacerbation rate will be derived according to the rule for the 
primary outcome variable in Section 3.1.
3.2.4 FEV 1 (L) pre-bronchodilator measured at the study center
FEV 1 (L) pre-bronchodilator is a key secondary efficacy endpoint of this study, and the 
change from baseline to Week [ADDRESS_745989]-ra ndomization visits (post Week 0, Visit 4) up to 
and including the end of the 56-week double-blind treatment visit (Week 56, Visit 19) will be 
used as the key secondary efficacy variable.  Details regarding the definition of baseline for 
FEV 1pre-bronchodilator is provided in Section 2.2.3 .
3.2.5 Healthcare resource utilization due to COPD
COPD related healthcare utilization information will be collected by [CONTACT_3786]/authorized delegate at each visit as specified in the protocol and recorded in the 
appropriate eCRF module.  
The number of days/times the following resources were utilized and corresponding annual 
rates w ill be presented for each subject:
! Ambulance transport
! Hospi[INVESTIGATOR_059], intensive care (days in intensive care)
! Hospi[INVESTIGATOR_059], general care (days in general care)
! Emergency room visit
! Visit to specialist
! Visit to primary health care physician
! Other health care visit
! Home visit, physician
! Home visit, other health care
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
29! Telephone call to physician
! Telephone call to nurse
! Telephone contact [CONTACT_568986]/health care provider
If multiple healthcare encounters are associated with 1 COPD exacerbation all the encounters 
will be counted for this endpoint.
3.3 Patient reported outcome variables 
COPD patient reported outcomes (PROs) are captured during site visits or using an electronic 
patient diary (i.e., ePRO). PROs at site visits include SGRQ, CAT, BDI/TDI, and PGIC. 
ePROs include EXACT-PRO, E-RS: COPD, daily diary metrics (rescue medication use and 
night-time awakenings), and EQ-5D-5L. Daily diary metrics will be recorded each day from the evening of Visit 2 to the morning of Visit 19.
The EQ-5D-5L will be completed weekly (7±2 days) starting from Week 0 (Visit 4) 
throughout Week 56 (Visit 19).
Baseline is defined as the last non-missing value before randomization for the COPD PROs 
and as the average of the last [ADDRESS_745990]-randomization biweekly means for daily metrics are calculated as the sum of all non-
missing daily measures/scores over the 14 da y window divided by [CONTACT_154562]-missing 
daily measures/scores. If more than 7 daily measures/scores (>50%) within that window are
missing, then the mean daily measure/score for that period is set to missing. The change from baseline to each post-randomization period will be used as secondary efficacy variables. No 
imputations will be made for missing values in the endpoint derivation although a multiple 
imputation sensitivity analysis is planned for SGRQ total score (see Section [IP_ADDRESS] ).
3.3.1 St. George’s Respi[INVESTIGATOR_6015] (SGRQ)
The change from baseline in SGRQ is a key secondary efficacy endpoint of this study, and the 
change from baseline to Week [ADDRESS_745991] obstruction diseases ( Jones et al. 1991 ). The questionnaire is divided into 2 parts: 
part 1 consists of 8 items pertaining to the severity of respi[INVESTIGATOR_568939] 4 weeks; and part 2 consists of 42 items related to the daily activity and psychosocial impacts of 
the individual’s respi[INVESTIGATOR_22342]. The SGRQ yields a total score and 3 domain scores 
(symptoms, activity, and impacts). The total score indicates the impact of disease on overall health status. This total score is e xpressed as a percentage of overall impairment, in which [ADDRESS_745992] possible health status. 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
30Likewise, the domain scores range from 0 to 100, with higher scores indicative of greater 
impairment. Specific details on the scoring algor ithms are provided by [CONTACT_310425] a user 
manual ( Jones et al. 2009 ).
The symptoms domain score will be set to missing if there are >2 missing items; activity 
domain score will be set to missing if there are >4 missing items; impacts domain score will 
be set to missing if there are >6 missing items; and total score will be set to missing if one of 
the 3 domain scores is missing.
Potential health status treatment benefits of benralizumab will be evaluated by [CONTACT_568987] 56 in SGRQ total score. A 4-point threshold will be used to 
define the response. If SGRQ total score at Week 56 has a @4-point decrease from baseline, it 
is defined as “improvement”; if it has a @4-point increase, it is defined as “worsening”. If the 
SGRQ total score change at Week 56 is not more than 4-points, it will be defined as “no 
change”. Missing SGRQ total score change at Week 56 will be considered as “not evaluable”. For the responder analysis of SGRQ, a responder will be defined as an individual who had 
“improvement” at Week 56 (ie, @4-point decrease in SGRQ total score at Week 56). Patients 
who had SGRQ total score change defined as “no change” or “worsening” will be considered as non-responders. If SGRQ total score change at Week [ADDRESS_745993] (CAT)
The CAT is an 8-item PRO developed to measure the impact of COPD on health status ( Jones 
et al. 2009 ). The instrument uses semantic differential 6-point response scales, which are 
defined by [CONTACT_568988]. Content includes items related to cough, phlegm, chest tightness, breathlessness going up hills/stairs, activity 
limitation at home, confidence leaving home, sleep, and energy. The CAT total score is the 
sum of all item responses. Scores range from [ADDRESS_745994] on health status.  A score cannot be calculated if >2 responses are missing; 
when one or two items are missing, their scores can be set to the average of the non-missing 
item scores.
3.3.3 Baseline/Transitional Dyspnea Index (BDI/TDI)
The BDI/TDI is an instrument developed to provide a multidimensional measure of dyspnea 
in relation to activities of daily living ( Mahler et al. 1984 ). The Baseline Dyspnea Index 
(BDI) provides a measure of dyspnea at a single state, the baseline, and the Transitional 
Dyspnea Index (TDI) evaluates changes in dyspnea from the baseline state. The instrument consists of three components: functional impairment, magnitude of task, and magnitude of 
effort. For the BDI, each of these three components are rated in five grades from 0 (severe) to 
4 (unimpaired), and are summed to form a baseline focal (total) score from 0 to 12. The BDI will be captured at Week -4 and Week 0 only.  For the TDI, changes in dyspnea are rated for 
each component by [CONTACT_406813] -3 (major deterioration) to +3 (major improvement), 
and are added to form a focal (total) TDI score from -9 to +9. Positive scores indicate an improvement, and a change from the BDI or a difference between treatments of 1 point has 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
31been estimated to constitute the minimum clinically important difference (MCID) ( Mahler et 
al. 2005 ).
A TDI responder will be defined as a patient who had a change from the BDI of at least 1
positive point at Week 56. For a patient who had a change of less than 1 positive point or non-evaluable change due to missing measurement at Week 56, the patient w ill be considered as a 
non-responder. 
3.3.4 Exacerbations of Chronic Pulmonary Disease Tool – Patient-reported 
Outcome (EXACT-PRO)
The EXACT-PRO is a 14-item PRO instrument developed to assess the frequency, severity 
and duration of COPD exacerbations ( Jones et al. 2011 , Leidy et al. 2011 ). The instrument 
was developed for daily, at home, administration using a handheld electronic device. 
Respondents are instructed to complete the electron ic diary (eDiary) each evening just prior to 
bedtime and to answer the questions while considering their experiences “today”. The daily 
EXACT-PRO total score has a range of 0-[ADDRESS_745995]-PRO daily total scores will be calculated according to the developer approved 
scoring algorithm. The total score will be used to identify event onset and recovery as well as 
the magnitude (severity) of the event. The base line total score will be the mean score within 
subject over the [ADDRESS_745996]-PRO total score @9 for 3 days or @12 for 2 
days indicate an event has occurred. Calculating event duration requires identification of the following 5 parameters: 1) onset; 2) 3-day rolling average; 3) maximum observed value; 4) 
threshold for improvement; and 5) recovery. The severity of an event is indicated by [CONTACT_568989] 
(highest) EXACT-PRO total score during an event. Complete details concerning variable calculation are provided in the scoring manual (Evidera, Inc. 2014).
For the production of summary statistics, the annual EXACT-PRO defined exacerbation rate
in each treatment group will be calculated using the same time-based approach as specified in 
Section 3.1.
3.3.5 Evaluating Respi[INVESTIGATOR_568940] 
(E-RS: COPD)
The E-RS: COPD is an 11-item PRO developed to evaluate the severity of respi[INVESTIGATOR_568941] ( Sexton et al. 2010 , Sexton et al. 2011 ). The E-RS: COPD is a subset of 
items from the EXACT-PRO. The E-RS: COPD was designed to be captured as part of the 
daily EXACT-PRO assessment. Summation of E-RS: COPD item responses produces a total 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
32score ranging from 0 to 40, with higher scores indicating greater severity. In addition to the 
total score, symptom domain scores can be calculated for breathlessness (5 items; score range: 
0–17), cough and sputum (3 items; score range: 0–11) and chest symptoms (3 items; score 
range: 0–12) by [CONTACT_244965] a respective domain. As with the total score, higher domain scores indicate greater severity.
Individual daily E-RS: COPD total and subscale scores will be calculated and summarised as 
a biweekly (14 day) mean. 
The biweekly mean is calculated as the sum of all non-missing daily measures/scores over 14 
sequential days divided by [CONTACT_154562]-missing daily measures/scores. If more than 7 
daily measures/scores (>50%) within that period are missing, then the mean daily measure/score for that period is set to missing. 
3.3.6 Total rescue medication use 
The number of rescue medication inhalations and nebulizer treatments taken will be recorded 
by [CONTACT_568990]. Daytime use is recorded in the evening, and night-
time use is recorded in the morning of the next calendar day. Total rescue medication use is 
the sum of daytime and night-time use. If either daytime or night-time use is missing, then total rescue medication use for that day is set to missing. 
Rescue medication usage will be summarised as the number of puffs with 1 instance of 
nebulizer use converted to 2 puffs. Inhaler usage will be reported as the number of puffs in a given period whereas nebulizer use will be reported as the number of times. The number of 
rescue medication inhalations and nebulizer treatmen ts captured in the eDiary each day will be 
calculated per patient. 
Total rescue medication use (inhaler and/or nebulizer), defined as the number of puffs per day 
will be calculated as follows:
Number of daytime inhaler puffs (recorded in the evening) + 2 x [number of daytime nebulizer 
times (recorded in the evening)] + number of night-time inhaler puffs (recorded the next 
morning) + 2 x [number of night-time nebulizer times (recorded the next morning)]
Total reliever inhaler puffs per day will be calculated as:
Number of daytime inhaler puffs (recorded in the evening) + number of night-time inhaler 
puffs (recorded the next morning)
Total nebulizer use (number of times) per day will be calculated as:
Number of daytime nebulizer times (recorded in the evening) + number of night-time 
nebulizer times (recorded in the next morning)
Biweekly mean rescue medication use (average puffs/day in total use) and change from 
baseline in the biweekly mean rescue medication use will be calculated.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
333.3.7 Nights with awakening due to respi[INVESTIGATOR_568942] a question about whether he/she woke up during the night 
due to respi[INVESTIGATOR_568943] a “yes” or “no” response.
The biweekly proportion of nights with nocturnal awakenings due to respi[INVESTIGATOR_568944]-missing night-time awakening data, and the corresponding change from baseline for 
each post-randomization period will be calculated.
3.3.8 European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L)
The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, 
slight problems, moderate problems, severe problems, and extreme problems) that reflect increasing levels of difficulty.
The subject will be asked to indicate his/her current health state by [CONTACT_406822] [ADDRESS_745997] imaginable health state.
The questionnaire will be completed by [CONTACT_568991] 56-week treatment period.
3.3.9 Clinician Global Impression of Change (CGIC) and Patient Global Impression 
of Change (PGIC)
Clinician Global Impression of Change (CGIC) and Patient Global Impression of Change 
(PGIC) instruments are used for an overall evaluation of response to treatment, conducted 
separately by [CONTACT_568992] a 7-point scale: 1=Very Much 
Improved; 2=Much Improved; 3=Minimally Improved; 4=No Change; 5=Minimally Worse; 
6=Much Worse; and 7=Very Much Worse.
The Investigator (clinician) and the patient will be asked to rate the degree of change in the 
overall COPD status compared to the randomization visit. The CGIC and PGIC assessments 
were added through a protocol amendment, therefore not all subjects in the full analysis set will have these assessments. Calculation of percentages will be based on the number of 
subjects in the full analysis set with a completed assessment. There will be no imputation for 
missing values.
The questionnaire will be completed by [CONTACT_568993] 16, 24, 32, and 
EOT.
Patients will also be categorized according to the following responses post-baseline, 
separately for CGIC and PGIC:
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
34! Very much improved, much improved, minimally improved \ ‘Improved’
! Very much improved, much improved \ ‘Much improved’
! Very much improved \ ‘Very much improved’
Agreement between CGIC and PGIC will be assessed at each visit, where agreement is 
achieved when both the patient and clinician provide the same response (e.g., if both the 
patient and clinician indicate a response of 1 (very much improved) at a particular visit, agreement is achieved for that visit). Agreement will also be assessed for categorized 
responses at each visit.
3.4 Subset analysis outcome variables
Additional assessments will be performed for a subset of subjects at designated sites, with
approximately 10-15% (54-81 subjects) in each treatment group.
3.4.[ADDRESS_745998] (6MWT)
The [ADDRESS_745999] (6MWT) measures the distance that a patient can quickly walk on a 
flat, hard surface in a period of [ADDRESS_746000]’s level of shortness of breath and fatigue, 
respectively, on a scale of 0 (no symptoms at all) to 10 (very, very severe (maximal)
symptoms). The breathlessness and fatigue scores will be measured before and after a subject performs the 6MWT. For subjects who discontinue IP, the last study assessment of 6MWT 
will be performed at the IPD visit.
3.4.2 Lung volumes
Lung volume subdivisions which include total lung capacity (TLC), residual volume (RV),
vital capacity (VC), functional residual capacity (FRC), and inspi[INVESTIGATOR_14008] (IC) will beperformed at the study center by [CONTACT_568994]. Lung volumes will be determined by  [CONTACT_568995]. At least 3 FRC 
values that agree within 5% (i.e., the difference between the highest and lowest value divided by [CONTACT_568996] <0.05) will be obtained and the mean value reported. For subjects who 
discontinue IP, the last study assessment of l ung volumes will be performed at the IPD visit.
3.4.3 Diffusion capacity of the lung for carbon monoxide (DL
CO)
Diffusion capacity for carbon monoxide (DL CO) will be performed at the study center 
according to the study schedule. The single breath technique will be used to determine the 
DL CO. Acceptable test criteria include an inspi[INVESTIGATOR_568945] 85% of VC; a 
stable breath hold of 10±2 seconds with no leaks, Valsalva or Mueller maneuvers; and 
expi[INVESTIGATOR_568946] [ADDRESS_746001] study assessment of DL COwill 
be performed at the IPD visit.
3.4.4 Sputum biomarkers / sputum cell count
Sputum will be collected according to the study schedules. Sputum will be analysed to
determine the differential cell count as well as to assess the levels of benralizumab related
pharmacodynamic biomarkers, biomarkers of eosinophil and basophil activation, eosinophil
and basophil growth factors, eosinophil recruitment, and inflammation associated with COPDincluding cytokines, chemokines, acute phase response proteins, and other inflammatory
mediators. For subjects who discontinue IP but agree to continue with regular on-site visits, 
sputum biomarkers and sputum cell count assessments will be performed according to st udy 
schedule until the end of the study (Week 56).
3.5 Safety outcome variables 
The following safety data will be collecte d: reported AEs (including SAEs), clinical 
chemistry, haematology, urinalysis, 12-lead electrocardiogram (ECG), physical examination 
and vital signs. 
All safety measurements will use all available data for analyses, including data from 
unscheduled visits and repeated measurements.
Change from baseline to each post-treatment time point where scheduled assessments were 
made will be calculated for relevant measurements. AEs will be summarised by [CONTACT_568997].
No safety data will be imputed. The handling of partial/missing dates for AEs and 
prior/concomitant medications is detailed in Appendix 8.2.
3.5.[ADDRESS_746002] version of the Medical Dictionary for Regulatory Activities 
(MedDRA) per the Data Management Plan. 
Adverse event data will be categorized according to their onset date into the following study
periods:
!AEs in the on-treatment period are defined as those with onset date between day of 
first dose of study treatment and the day of the scheduled end of treatment (EOT) visit
(defined by [CONTACT_568998] 56 +/- 7 days) for patients who complete study 
treatment. For instances where a patient does not attend EOT visit within the protocol 
defined window or prematurely discontinues IP, AEs occurring on or before the last 
dose of study medication +[ADDRESS_746003]-treatment period.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
36!AEs in the on-study period are defined as those with onset date on or after the day of 
first dose of study treatment.
!AEs in the post-treatment period are defined as those with onset date after the on-
treatment period defined above.
If an AE has a missing onset date then unless the stop date of the AE indicates otherwise, this 
will be considered an ongoing AE. Similarly, if an AE has a partial onset date, then unless the 
partial onset date or the stop date indicates otherwise, this will be considered an ongoing AE.
3.5.2 Laboratory variables
Blood and urine samples for determination of clinical chemistry, haematology and urinalysis 
parameters will be taken at the times detailed in  the CSP, and will be assessed in a central 
laboratory. The parameters outlined in Section 5.2.6, Tables 4 and 5 of the CSP will be 
collected. 
In summaries, figures, and listings, lab results and normal ranges will be presented in System 
International (SI) units. Eosinophils data will be presented in both SI and conventional units 
(cells/QL) in summaries. 
For the purposes of clinical chemistry, haematology, and urinalysis shift tables, baseline will 
be defined as the last available non-missi ng assessment prior to first dose of randomised 
treatment, and maximum or minimum value post-baseline will be calculated over the entire 
post-baseline period, including the post-treatment period.
Changes in haematology and clinical chemistry variables between baseline and each post-
baseline assessment will be calculated.  The change from baseline is defined as the post-
baseline visit value minus the baseline visit value. There will be no imputation for missing values.  For values recorded with a leading greater than or less than (‘>’, ‘<’) symbol, the 
reported numeric value will be used for analysis and the value with the symbol will be 
included in the listings, unless otherwise specified. For example, a value of <0.01 will be analysed as 0.01 and listed as <0.01.
Absolute values will be compared to the relevant reference range and classified as low (below 
range), normal (within range or on limits) or high (above range). The central reference ranges will be used for laboratory variables. All values (absolute and change) falling outside the 
reference ranges will be flagged.
Urinalysis data categorized as negative (0), positive (+), or strongly positive (++, +++, or 
>+++) or equivalent categories as reported by [CONTACT_6626].
For the liver function tests: aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT) and total bilirubin (TBL), the multiple of the central laboratory upper limit of the normal (ULN) range will be 
calculated for each data point.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
37Multiple = Value / ULN
That is, if the ALT value was 72 IU/L (ULN=36) then the multiple would be 2.
Patients who meet any of the following criteria  at any point during the study will be flagged:
! AST @ 3x ULN 
! ALT @ 3x ULN 
! TBL @ 2xULN
3.5.3 Twelve-lead electrocardiogram
Twelve-lead electrocardiogram (ECG) measurements will be recorded in accordance with the 
protocol, with the baseline visit being defined as the last available non-missing measurement 
prior to first dose of randomised treatment. 
The outcome of the overall evaluation is to be recorded as normal/abnormal in the eCRF by 
[CONTACT_737]/authorized delegate, with any abnormalities being recorded as not clinically 
significant or clinically significant.
The ECG will also be transferred to a central reader.3.5.4 Physical examination
Complete and brief physical examinations will be performed at time points specified in Tables 
2 and 3 of the CSP. Assessments will be dependent on whether the examination is complete or brief, as described in Section 5.2 of the CSP. For the brief physical examination, only 
information on whether the assessment was performed or not is to be recorded.
Each component of the baseline complete physical examination will be recorded as normal or 
abnormal. Each component of the follow-up complete physical examinations will be recorded 
as normal, same as baseline, or new/aggravated.
Any new finding(s) or aggravated existing finding(s), judged as clinically significant by [CONTACT_3786], will be reported as an AE.
3.5.5 Vital signs
Pre-dose vital signs (pulse, systolic blood pressure, diastolic blood pressure, respi[INVESTIGATOR_1487],
and body temperature) will be obtained in accordance with the visit schedule provided in the 
CSP.
Changes in vital signs variables between baseline and each subsequent scheduled assessment 
will be calculated. Baseline is defined as the last value prior to the first dose of randomised
treatment. The change from baseline is defined as the post-baseline visit value minus the baseline visit value. There will be no imputation for missing values.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
38Absolute values will be compared to the reference ranges in Table 3 and classified as low 
(below range), normal (within range or on limits) or high (above range). All values (absolute 
and change) falling outside the reference ranges will be flagged.
Table [ADDRESS_746004] Units Lower Limit Upper Limit
Diastolic Blood Pressure (DBP) mmHg 60 120
Systolic Blood Pressure (SBP) mmHg 100 160
Pulse Rate Beats/min 40 120Respi[INVESTIGATOR_568947]/min 8 28
Body Temperature Celsius 36.5 38
Weight kg 40 200
Body mass index (BMI) will be calculated from the height and weight as follows:
BMI (kg/m2)=weight (kg)/(height (m))2
3.6 Pharmacokinetic variables
Blood samples (processed to serum) for pharmacokinetic assessments will be collected from 
all sub jects at baseline prior to first benralizumab administration at Week 0 Day 1, at Weeks 
4, 8, 16, 24, 32, 40, 48, and 56 before benralizumab administrations during the treatment 
period, and at the Week 60 follow-up visit. Serum concentrations of benralizumab will be 
determined using a validated electrochemiluminescent (ECL) immunoassay. Results below 
the lower limit of quantification (BLQ) will be set to LLOQ/2 for analysis and will be listed as 
<LLOQ.
3.7 Immunogenicity variables
Anti-drug antibodies (ADA) variables, such as ADA responses, will be generated and 
analysed as per the details in Appendix 8.3.
4. ANALYSIS METHODS
4.[ADDRESS_746005] at Visit 4 (Week 0) and the conclusion of Visit 19 
(Week 56), inclusive. This includes data regardless of whether study treatment was prematurely discontinued, or delayed, and/or irrespective of protocol adherence, unless the 
patient withdraws consent to study participati on. The statistical analyses will compare each 
dosing regimen of benralizumab to placebo. The analysis of secondary safety endpoints will 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.[ADDRESS_746006] at Visit 4 (Week 0) and the conclusion 
of the scheduled post-treatment follow-up visit (Week 60), inclusive.
The data analyses will be conducted using the SAS® System (SAS Institute Inc., Cary, NC). 
All SAS® programs used to generate analytical results will be developed and validated 
according to [COMPANY_008] SAS® programming standards and validation procedures.
Pharmacokinetic analyses will be performed using NONMEM or other appropriate software. 
Summary data will be presented in tabular f ormat by [CONTACT_1570]. Categorical data will be 
summarised by [CONTACT_96776]. Continuous variables 
for parametric data will be summarised by [CONTACT_387460] N, mean, SD, median, and range. All clinical data will be listed. Data listings will be sorted by [CONTACT_568999].
Following ongoing review of protocol deviations during the trial conduct, a small number of 
randomised subjects were identified as not on protocol-specified double (ICS/LABA, 
LABA/LAMA) or triple (ICS/LABA/LAMA) therapy at baseline.  As such, these subjects 
have missing values for the background therapy covariate used in the statistical analyses. In order to ensure all patients in the full analysis set contribute to the primary and secondary 
endpoint inferential analyses, the following imputation rules will be applied. Each of these 
patients will be documented as having an important protocol deviation and summarised as described in Section 2.2.1 . 
! Subjects on ICS alone will be categorized as ICS/LABA
! Subjects on LABA alone will be categorized as LABA/LAMA
! Subjects on LAMA alone will be categorized as LABA/LAMA
! Subjects on ICS/LAMA alone will be categorized as ICS/LABA
All hypothesis testing will be reported using 2-sided tests. All p-values will be nominal and 
will be displayed in SAS pvalue6.4 format.
The absolute change from baseline is computed as ( visit value – baseline value ). Percent 
change from baseline is computed as (( visit value – baseline value )/baseline value ) × 100%. If 
either a visit value or the baseline visit value is missing, the absolute change from baseline 
value and the percent change from baseline will also be set to missing. If baseline value is 
zero, the percent change will be set to missing. 
4.1.[ADDRESS_746007] the primary (annual COPD exacerbation rate) and 2 key 
secondary endpoints (change from baseline in FEV
1 (L) pre-bronchodilator at Week 56 and 
change from baseline in SGRQ total score at Week 56), for each of the 2 dosing regimens (for 
patients with baseline blood eosinophils >220/ KL), a testing strategy will be followed to 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
40control the overall type I error rate. The testing strategy will be according to the following 
gatekeepi[INVESTIGATOR_124502]:
Step 1: Perform the 2 tests of annual COPD exacerbation rate ([ADDRESS_746008] for each dose regimen vs. 
placebo) at the family wise error rate (FWER) of 0.04 using a Hochberg Procedure (
Hochberg 1988 ). If both p-values are less than 0.04, then proceed to Step 2; else if the smaller 
p-value is less than 0.02 then proceed to Step 2a; otherwise no null hypothesis is rejected.
Step 2: Test the 2 key secondary endpoints for both dose regimens as 1 family at the FWER of 
0.05 using a Holm Procedure ( Holm 1979 ).
Step 2a: Test the [ADDRESS_746009] statistics for the annual COPD exacerbation rate in Step 1 is 
positive, due to the common placebo group, the FWER of the Hochberg Procedure in Step 1 is 
strongly controlled at 0.04. The overall FWER of  the gatekeepi[INVESTIGATOR_568948] 0.05.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
41The gatekeepi[INVESTIGATOR_568949]:
4.2 Analysis methods
4.2.1 Patient disposition
Patient disposition will be summarised using the all patients analysis set and separately for 
patients in the full analysis set with baseline eosinophil count @220/QL and <220/ QL. The total 
number of patients will be summarised for the following groups: those who enrolled and those 
who were not randomised (and reason). The number and percentage of patients within each treatment group will be presented by [CONTACT_68180]: randomised, did not receive 
treatment with study drug, received treatment with study drug, completed treatment with study 
drug, completed treatment but discontinued study, discontinued treatment with study drug (and reason), discontinued treatment with study drug but completed study, completed study, 
and withdrawn from study (and reason).
Screen failure information will be listed for the all patients analysis set.The number of patient randomised by [CONTACT_569000].Test exacerbation rate 
of the two doses at 
0.[ADDRESS_746010] the 2 secondary 
for the smaller p-value 
dose at 0.01 using 
Holm Procedure
no
yesMax(P1,P2)<0.04?
Test the 2 key secondary 
endpoints for both dose 
regimens at
Holm ProcedureStop and no null 
hypothesis is rejectedMin(P1, P2)< 0.02?
noyes
0.05 using 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
424.2.2 Demography data and patient characteristics
Demography data such as age, gender, race, and ethn icity w ill be summarised by [CONTACT_569001], and for patients in the full analysis set with 
baseline blood eosinophil counts @220/KL and baseline blood eosinophil counts <220/ KL. Age 
will be derived from the date of informed consent-date of birth, rounded down to the nearest 
integer. For patients in countries where date of bi rth is not recorded, the age as recorded in the 
electronic case report form (eCRF) will be used.
Medical, surgical, and cardiovascular historie s (including comorbidities of arrhythmia, 
ischemic or structural cardiac disease, and systemic inflammatory and peripheral vascular 
disorder) w ill be su mmarised by [CONTACT_569002] <220/ KL and blood eosinophil counts @220/KL:
! Patient characteristics (weight, height, BMI, baseline eosinophil count as used for 
stratification for randomization, and historic eosinophil count)
! Baseline lung function data (pre- and post-BD FEV 1(L), FEV 1(% PN), FVC (L), 
FVC (% PN), FEV 1/FVC, and reversibility)
! Respi[INVESTIGATOR_568950]
! Nicotine use and consumption
4.2.3 Prior and concomitant medications
The number and percentage of patients taking maintenance COPD medications (double or 
triple therapy) at baseline will be summarised based on actual medication therapy group, not 
the imputed therapy group used for the statistical analysis (Section 4.1).
The number and percentage of patients who take prior medications, those who take allowed 
concomitant medications, and those who take disallowed concomitant medications during the study will be presented by  [CONTACT_1570]. Concomitant medications will be classified 
according to the [COMPANY_008] Drug Dictionary (AZDD). The summary tables will present data 
by [CONTACT_569003].
4.2.[ADDRESS_746011] administration will be calculated in days as:
Last dose date of IP-first dose date of IP+1and will be summarised by [CONTACT_569004].
Study treatment compliance will be summarised by [CONTACT_569005]: 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
43Study treatment compliance = (total doses administered/total doses expected) x 100. 
Patients who received no study treatment will have zero compliance. Total number of doses 
expected includes all visits with protocol scheduled IP administration on or before a subject's 
IP discontinuation or treatment complete date.
4.2.5 Primary outcome variable
[IP_ADDRESS] Primary analysis
The primary efficacy variable is the annual COPD exacerbation rate and the primary analysis 
is to compare the annual COPD exacerbation rate of each benralizumab dose regimen with 
placebo in patients with baseline blood eosinophil counts @220/KL. Patients will be analysed
using the full analysis set according to randomised treatment.
For each of the 2 benralizumab dose regimens, the null hypothesis is that the exacerbation rate 
on benralizumab is equal to the exacerbation rate on placebo. The alternative hypothesis is that the exacerbation rate on benralizumab is not equal to the exacerbation rate on placebo, ie,
H
0: Rate ratio (benralizumab vs Placebo) = 1
Ha: Rate ratio (benralizumab vs Placebo) < 1
Annual exacerbation rate in each of the 2 benralizumab dose regimen groups will be 
compared to annual exacerbation rate in the placebo group using a negative binomial modelfor the primary analysis. The response variable in the model will be the number of COPD 
exacerbations experienced by a patient over the 56-week double-blind treatment period. The 
model will include covariates of treatment group, eosinophil cohort (220-299/ KL or @300/KL),
region, background therapy (ICS/LABA, LABA/LAMA, or ICS/LABA/LAMA), and the 
number of exacerbations in the previous year. The logarithm of the patient’s corresponding 
follow-up time will be used as an offset variable in the model to adjust for patients having different exposure times during which the events occur.
The COPD exacerbation rate and the corresponding 95% confidence interval (CI) within each 
treatment group will be presented. The estimated treatment difference from placebo (ie, the absolute difference between benralizumab and placebo, and the rate ratio of benralizumab 
versus placebo), corresponding 95% CI, and 2-sided p-values for the rate ratio will be 
presented. Marginal standardization methods will be used on the model estimates for all negative binomial analyses, unless otherwise specified. 
The above negative binomial analysis will be repeated for the following: 
! Baseline blood eosinophil counts <220/ KL. Eosinophil cohort (220-299/ KL or 
@300/KL) will not be a covariate in this model.
! Cumulative baseline blood eosinophil count categories (<150/ KL,@150/KL, 
<220/KL,@220/KL, <300/KL, @300/KL, <400/KL, @400/KL). Eosinophil cohort (220-
299/KL or @300/KL) will not be a covariate in this model.  Non-marginal estimates 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
44will be weighted by [CONTACT_569006] 
@220/KL and <220/ KL to adjust for the approximately 2:1 rando mization ratio in 
cumulative baseline blood eosinophil count categories. Patients with missing 
baseline blood eosinophil values from central laboratory are excluded.
! Cumulative historical blood eosinophil count categories (<150/ KL,@150/KL, 
<220/KL,@220/KL, <300/KL, @300/KL, <400/KL, @400/KL). Eosinophil cohort (220-
299/KL or @300/KL) will not be a covariate in this model.
! On-treatment exacerbations in patients with baseline blood eosinophil counts
@220/KL (i.e., excluding assessments after the EOT or IPD visit).
! Exacerbations that result in hospi[INVESTIGATOR_568951] @220/KL. In the statistical model, the continuous covariate 
number of exacerbations in the previous year will be replaced by a binary covariate: 
exacerbation associated with a hospi[INVESTIGATOR_568952] (Yes, No).
! Exacerbations in patients with baseline blood eosinophil counts @220/KL, excluding 
exacerbations outside of the EOT visit window.
! Exacerbations in patients with baseline blood eosinophil counts @220/KL, using the 
data truncated at the point when subjects switched their background therapi[INVESTIGATOR_014].
! Exacerbations by [CONTACT_425699]/or severity of exacerbations during the previous year
in patients with baseline blood eosinophil counts @220/KL
! U2 exacerbations
! @3 exacerbations
! Only severe exacerbations
! @1 severe exacerbation
! @2 severe exacerbations
! Only moderate exacerbations
! @2 moderate exacerbations only
! @3 moderate exacerbations only
Further subgroup analyses for the COPD exacerbation rate are outlined in Section [IP_ADDRESS] .  
Additional analyses to assess the robustness of the primary analysis results to missing data are 
outlined in Appendix 8.1. Marginal standardization methods will not be applied to missing 
data analyses.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
45COPD exacerbation summary s tatistics w ill be presented based on the full analysis set by 
[CONTACT_569007] @220/KL and <220/ KL. The
individual exacerbation criteria (use of systemic corticosteroids, use of antibiotics, and 
inpatient hospi[INVESTIGATOR_568933]) will also be summarised descriptively.
[IP_ADDRESS] Subgroup analysis for the primary outcome variable
To explore the uniformity of the detected overall treatment effect on the primary efficacy 
variable, subgroup analyses and statistical modelling including testing for interaction between treatment and covariates will be performed in patients with baseline blood eosinophil counts 
@220/KL for the following factors: background therapy (ICS/LABA, LABA/LAMA, or 
ICS/LABA/LAMA) including imputation, baseline ICS use (Yes, No), baseline theophylline use (Yes, No), gender, age group categories (<65, @65 years), geographic region (Asia, 
Eastern Europe, Europe, North America, and rest of world), smoking status (current, former), 
BMI (U35, >35 kg/m
2and U21, >21 kg/m2), the number of exacerbations during the previous 
year (U2, @3 exacerbations), race (White, Asian, or Other), baseline IgE concentration 
(<150KU/L, @150KU/L ), atopic status (Yes, No), COTE index (<4, @4, Divo et al. 2012 ), and 
baseline GOLD classification of severity of airflow limitation in COPD (moderate, severe, very severe) based on GOLD 2014 . 
An additional subgroup analysis using the methodology outlined above will be conducted 
using baseline blood eosinophil count categories (<150/ KL, 150-219/ KL, 220-299/ KL, 300-
399/KL, @400/KL). Eosinophil cohort (220-299/ KL or @300/KL) will not be a covariate in these 
models. Patients with missing baseline blood eosinophil values from central laboratory are 
excluded.
For each of the subgroup factors, a separate negative binomial regression model will be fitted 
using the same model terms as used for the primary analysis (described in Section [IP_ADDRESS] , 
with additional terms for the subgroup main effect and the treatment by [CONTACT_226418]).Region is not a covariate if it is the subgroup; background therapy is not a covariate if 
background therapy or baseline ICS use is the subgroup; and number of exacerbations is a not 
a covariate if it is the subgroup.
Similar outputs will be presented for each subgroup as for the primary analysis. The p-value 
for the interaction term by [CONTACT_81591] w ill be presented in the summary tables and
forest plots.
It is important to note that the study has not been designed or powered to assess efficacy 
within any of these pre-defined subgroups, and as such these analyses are considered as 
exploratory.
[IP_ADDRESS] Supportive analysis for the primary outcome variable
As a supportive analysis, the annual exacerbation rate will be calculated based on 
exacerbations that are associated w ith a hospi [INVESTIGATOR_568953] [IP_ADDRESS] , for patients with baseline eosinophil count @220/KL. In 
the statistical model, the continuous covariate number of exacerbations in the previous year 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
46will be replaced by a binary covariate: exace rbation associated wi th a hospi[INVESTIGATOR_568954] (Yes, No).
4.2.6 Secondary efficacy outcome variables
All secondary efficacy endpoints will be summarised separately by [CONTACT_569008] @220/KL and <220/ KL, with formal statistical analyses conducted in the baseline blood 
eosinophil counts @220/KL group.
Additional formal statistical analyses in the <220/KL group will be conducted for the 
multiplicity protected key secondary endpoints (change from baseline in FEV 1 (L) pre-
bronchodilator at Week 56 and change from baseline in SGRQ total score at Week 56), where 
presentation by [CONTACT_569009]. 
In addition, the key secondary endpoints will be  analysed pooling together data from patients 
with baseline blood eosinophil counts <220/ KL from this study and study D3251C00004. The 
pooled analysis will be elaborated in a separate SAP.
[IP_ADDRESS] Proportion of subjects with @1 COPD exacerbation
The proportion of subjects with @1 COPD exacerbation during the 56 weeks treatment period 
will be addressed as a supportive variable to the primary objective for patients with baseline 
blood eosinophil counts @220/KL. The proportion in each of the 2 benralizumab dose regimen 
groups w ill be compared with the proportion in the placebo group using a Cochran–Mantel–
Haenszel test controlling for eosinophil cohort ( @220-299/QL or 300/QL), region, and 
background therapy (ICS/LABA, LABA/LAMA, or ICS/LABA/LAMA) as covariates. 
The results of the analyses will be presented using odds ratio, together with associated 95% CI 
and 2-sided p-values for each active dose regimen versus placebo. The number and percentage 
of patients with @1 COPD exacerbation will also be summarised by [CONTACT_444987]. 
[IP_ADDRESS] Time to first COPD exacerbation
Time to first COPD exacerbation will be analysed as another supportive efficacy variable to 
the primary objective to explore the extent to which treatment with benralizumab delays the 
time to first exacerbation compared with placebo. A Cox proportional hazard model will be 
fitted to the data with the covariates of treatment, eosinophil cohort (220-299/ QL or @300/KL), 
region, background therapy (ICS/LABA, LABA/LAMA, or ICS/LABA/LAMA), and number 
of exacerbations in the previous year. This analysis will also be repeated for the time to first 
COPD exacerbation associated with a hospi[INVESTIGATOR_568955] a hospi[INVESTIGATOR_568952]  (Yes, No) will be included as a covariate 
instead of number of exacerbations in the previous year.
Results of these analyses will be summarised  as hazard ratios, 95% CI and p-values for 
patients with baseline blood eosinophil counts @220/KL.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.[ADDRESS_746012] COPD exacerbation will be displayed graphically using a Kaplan-Meier plot, 
separately for patients with baseline blood eosinophil counts @220/KL and <220/ KL.
The percentage of patients who are exacerbation free at Week 26 and Week 52 will be 
estimated for each treatment group. These percentages will be estimated using the Kaplan-Meier technique. 
[IP_ADDRESS] FEV
1(L) pre-bronchodilator measured at the study centre
Change from baseline in FEV 1(L) pre-bronchodilator at Week 56 in the baseline blood 
eosinophil counts @220/KL group is a multiplicity protected key secondary endpoint (Section 
4.1.1 ). 
Summary statistics of the change from baseline in FEV 1(L) pre-bronchodilator at the study 
center will be produced by [CONTACT_6982]. 
Change from baseline in FEV 1(L) pre-bronchodilator t hrough W eek [ADDRESS_746013] model for repeated measures (MMRM) analysis on patients with a baseline FEV
1 (L) 
pre-bronchodilator and at least [ADDRESS_746014]-baseline FEV 1 (L) pre-bronchodilator assessment.
The dependent variable will be the change from baseline in FEV 1 (L) pre-bronchodilator at 
post-baseline protocol-specified visits (up to the EOT visit). Treatment group will be fitted as 
the explanatory variable, and baseline FEV 1 (L) pre-bronchodilator , region, eosinophil cohort 
(220-299/ KL or @300/KL), background therapy (ICS/LABA, LABA/LAMA, or 
ICS/LABA/LAMA), visit, and treatment*visit interaction as fixed effects. The covariance 
matrices will be assumed in the following order, unstructured, Toeplitz, first-order 
autoregressive, compound symmetric, variance components. If the procedure doesn’t converge, the next covariance matrix will be used in the order. The model is:
Change from baseline in FEV
1 (L) pre-bronchodilator = Treatment group + baseline FEV 1 (L) 
pre-bronchodilator + region + eosinophil cohort (220-299/ @L or A300/@L)+background 
therapy (ICS/LABA, LABA/LAMA, or ICS/LABA/LAMA) + visit + treatment*visit
Results will be presented in terms of least square means (LSMEANS), treatment differences 
in LSMEANS, 95% CI and p-values. The results at Week [ADDRESS_746015].
The above MMRM analysis will be repeated for the following: 
! Baseline blood eosinophil counts <220/ KL. Eosinophil cohort (220-299/ KL or 
@300/KL) will not be a covariate in this model. 
! Cumulative baseline blood eosinophil count categories (<150/ KL,@150/KL, 
<220/KL,@220/KL, <300/KL, @300/KL, <400/KL, @400/KL). Eosinophil cohort (220-
299/KL or @300/KL) will not be a covariate in this model.  Estimates will be 
weighted by [CONTACT_569006] @220/KL 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
48and <220/ KL to adjust for the approximately 2:1 randomization ratio in cumulative 
baseline blood eosinophil count categories.
! On-treatment pre-bronchodilator FEV 1in patients with baseline blood eosinophil 
counts @220/KL (ie, excluding assessments after the EOT or IPD visit).
! By [CONTACT_569010] ( U2, @3) in patients with 
baseline blood eosinophil counts @220/KL.
Additional analyses to assess the robustness of the repeated measures analysis to missing data 
are outlined in Appendix 8.1.  
A subgroup analysis, using the same MMRM model defined above with additional terms for 
the subgroup main effect and the treatment by [CONTACT_226418], will be conducted for the 
following factor based on the full analysis set:
! Baseline blood eosinophil count categories (<150/ KL, 150-219/ KL, 220-299/ KL, 
300-399/KL, @400/KL). Eosinophil cohort (220-299/ KL or @300/KL) will not be a 
covariate in this model.
[IP_ADDRESS] St. George’s Respi[INVESTIGATOR_6015] (SGRQ)
Change from baseline in SGRQ total score at Week 56 in the baseline blood eosinophil counts 
@220/KL group is a multiplicity protected key secondary endpoint (Section 4.1.1 ). 
Summary statistics for change from baseline in SGRQ total score and the domain scores will 
be produced by [CONTACT_6982].
Change from baseline in SGRQ total score and the 3 domain scores (symptoms, activity, and 
impacts) over 56 weeks will be analysed separately using a similar model as the above model 
for change from baseline in FEV 1 (L) pre-bronchodilator , described in Section [IP_ADDRESS] . Results 
will be presented in terms of LSMEANS, treatment differences in LSMEANS, 95% CI and p-
values for all visits. The results at Week [ADDRESS_746016].
The above MMRM analysis will be repeated for the following: 
! Baseline blood eosinophil counts <220/ KL. Eosinophil cohort (220-299/ KL or 
@300/KL) will not be a covariate in this model. 
! Cumulative baseline blood eosinophil count categories (<150/ KL,@150/KL, 
<220/KL,@220/KL, <300/KL, @300/KL, <400/KL, @400/KL). Eosinophil cohort (220-
299/KL or @300/KL) will not be a covariate in this model.  Estimates will be 
weighted by [CONTACT_569011] @220/KL 
and <220/ KL to adjust for the approximately 2:1 rando mization ratio in cumulative 
baseline blood eosinophil count categories.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
49! On-treatment SGRQ total score in patients with baseline blood eosinophil counts 
@220/KL (i.e., excluding assessments after the EOT or IPD visit).
Additional analyses to assess the robustness of the repeated measures analysis for SGRQ total 
score to missing data are outlined in Appendix 8.1.  
A subgroup analysis, using the same MMRM model defined above with additional terms for 
the subgroup main effect and the treatment by [CONTACT_226418], will be conducted for the 
following factor based on the full analysis set:
! Baseline blood eosinophil count categories (<150/ KL, 150-219/ KL, 220-299/ KL, 
300-399/KL, @400/KL). Eosinophil cohort (220-299/ KL or @300/KL) will not be a 
covariate in this model.
The cumulative distribution function of absolute changes from baseline in SGRQ total score at 
Week 56 will be also plotted in a figure.
The proportion of subjects in terms of SGRQ total score response status (improvement, 
worsening, no change, and not evaluable) at Week 56 will be summarised descriptively by 
[CONTACT_1570]. The proportion of subjects with @4-point decrease (improvement) in SGRQ 
total score at Week 56 in each of the 2 benralizumab dose groups will be compared with the 
proportion in the placebo group using a Cochran–Mantel–Haenszel (CMH) test controlling for 
eosinophil cohort (220-299 or @300/QL), region, and background therapy (ICS/LABA, 
LABA/LAMA, or ICS/LABA/LAMA). The results of the analyses will be presented as odds 
ratios with associated 95% CI and 2-sided p- value for each active dose regimen versus 
placebo. A similar CMH analysis will be performed using last observation carried forward (LOCF) for patients with non-evaluable response status at Week 56.
[IP_ADDRESS] COPD assessment tool (CAT)
The CAT total scores and changes from baseline will be summarised by [CONTACT_10659].
Change from baseline in CA T score through Week 56 w ill be analysed using a s imilar model 
as for the change from baseline in FEV
1 (L) pre-bronchodilator described in Section [IP_ADDRESS] .
Results will be presented in terms of LSMEANS, treatment differences in LSMEANS, 95% 
CI and p-values for all visits.
[IP_ADDRESS] Baseline/Transitional Dyspnea Index (BDI/TDI)
The BDI focal (total) score and component scores will be summarised by [CONTACT_1570], and 
the TDI focal (total) score and component scores will be summarised by [CONTACT_29013].
Change from baseline in TDI focal (total) score through Week 56 w ill be analysed using a 
similar MMRM model as for the analysis of change from baseline in FEV 1 (L) pre-
bronchodilator described in Section [IP_ADDRESS] , with BDI focal (total) score as the baseline value 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
50for TDI focal (total) score. Results will be  presented in terms of LSMEANS, treatment 
differences in LSMEANS, 95% CI and p-values for all visits.
TDI responder (yes/no) at Week 56 will be anal ysed using a logistic regression model with 
covariates of treatment group, BDI score, eosinophil cohort (220-299/ KL or @300/KL), region, 
and background therapy (ICS/LABA, LABA/LAMA, or ICS/LABA/LAMA).
[IP_ADDRESS] Exacerbations of Chronic Pulmonary Disease Tool – Patient-reported 
Outcome (EXACT-PRO)
Summary statistics of the EXACT-PRO event frequency, duration, and severity will be 
produced by [CONTACT_1570].
Annual rate of EXACT-PRO defined exacerbati on will be analysed using the method 
described for the primary analysis in Section [IP_ADDRESS] for patients in the full analysis set with 
baseline eosinophil count @220/QL.
[IP_ADDRESS] Evaluating Respi[INVESTIGATOR_568940] 
(E-RS: COPD)
The E-RS: COPD total scores and domain scores as well as changes from baseline will be 
summarised by [CONTACT_10659].
Change from baseline in E-RS: COPD total score and domain scores will be analysed
separately using a similar MMRM model as for the analysis of change from baseline in FEV 1 
(L) pre-bronchodilator described in Section [IP_ADDRESS] . Results will be presented in terms of 
LSMEANS, treatment differences in LSMEANS, 95% CI and p-values for all visits.
[IP_ADDRESS] Medication Use
Total rescue medication use
Total rescue medication use and change from baseline will be summarised by [CONTACT_103913].
Change from baseline in total rescue medication use (average puffs/day) will be analysed
using the same MMRM method for FEV 1(L) pre-bronchodilator as described in Section 
[IP_ADDRESS] , for patients with baseline blood eosinophil count @220/KL.
Background medication use
Descriptive statistics of patients who switched their background medication will be 
summarised for the on-treatment and post-treatment periods as defined in Section 3.5.1 . A
shift table will be produced to summarise the types of therapi[INVESTIGATOR_568956]. In addition, the number of patients who switched their background medication 
during the on-treatment period will be plo tted over time by [CONTACT_569012]: ICS/LABA LABA/LAMA, LABA/LAMA ICS/LABA, ICS/LABA 
ICS/LABA/LAMA, LABA/LAMA ICS/LABA/LAMA, ICS/LABA/LAMA 
ICS/LABA, and ICS/LABA/LAMA LABA/LAMA.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
51Glucocorticoid use
The total number of days patients were on systemic glucocorticoid due to COPD exacerbation 
during the treatment period will be summarised by [CONTACT_1570].
[IP_ADDRESS] Nights with awakening due to respi[INVESTIGATOR_568957].
Change from baseline in the proportion of nights with awakening due to respi[INVESTIGATOR_568958] 1(L) pre-bronchodilator as described 
in Section [IP_ADDRESS] , for patients with baseline blood eosinophil count @220/KL.
[IP_ADDRESS] Healthcare resource utilization 
The number and rate of patients with COPD specific resource utilization during the treatment 
period will be summarised by [CONTACT_1570].
4.2.7 Additional modelling for primary and key secondary endpoints
Additional modelling will be performed to assess the relationship in each treatment group 
between the primary and key secondary endpoints with baseline blood eosinophil count (as a 
continuous variable) and number of exacerbations in the previous year.  The following plots 
will be produced:
! Annual COPD exacerbation rate based on baseline blood eosinophil counts
! Annual COPD exacerbation rate based on number of exacerbations in the previous 
year
! Change from baseline in FEV 1(L) pre-bronchodilator at end of treatment based on 
baseline blood eosinophil counts
! Change from baseline in SGRQ total score at end of treatment based on baseline 
blood eosinophil counts
Additional sensitivity analyses will be conducted on the primary and key secondary endpoints 
to investigate the sensitivity of the efficacy conclusions upon removal of patient data from sites with data anomalies. The primary assessment of benefit-risk will be based on the full 
analysis set in patients with baseline eosinophils @220/KL. Data anomalies may include but are 
not restricted to: sites with multiple benralizumab PK concentration level anomalies (e.g. patients with PK levels persistently below LLOQ or excessive PK concentrations); sites with 
high correlations in entry time of ePRO data; sites with available ePRO data post-death; or 
sites closed due to quality issues. 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
524.2.8 Exploratory Objectives
[IP_ADDRESS] European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L)
The EQ-5D-5L responses from each dimension and the visual analog scale, and changes from 
baseline, will be summarised by [CONTACT_6982].
Shift tables will also be produced for each dimension. 
[IP_ADDRESS] Clinician Global Impression of Change (CGIC) and Patient Global Impression 
of Change (PGIC)
The CGIC and PGIC responses will be summarised by [CONTACT_6982]. The number 
and percentage of patients will be presented for CGIC, PGIC, and for agreement in CGIC and 
PGIC. 
The number and percentage of patients defined as responders based on categorized responses 
for CGIC and PGIC (improved, much improved, very much improved) will also be presented 
by [CONTACT_6982].
PGIC responses will be excluded from all analyses if only caregiver or other is the respondent.[IP_ADDRESS] Blood eosinophils
An important marker of the biological activity of benralizumab is the reduction in eosinophils 
in the peripheral blood. 
Absolute blood eosinophil count assessed by a central laboratory as a part of safety 
haematology testing at Week -4 (Visit 1) will be used as the baseline blood eosinophil 
measure to inform primary and secondary efficacy of benralizumab. Absolute eosinophil counts along with their absolute changes from baseline, and percentage changes from baseline 
will be summarised by [CONTACT_569013] (cells/ QL). Baseline 
is defined as the last non-missing value prior to the first dose of study treatment. Percent change from baseline in eosinophil counts will be compared between each benralizumab 
group and the placebo group using a MMRM analysis, as defined for analysis of FEV
1pre-
bronchodilator in Section [IP_ADDRESS] . Results will be presented separately by [CONTACT_569014] (<220/ KL and @220/KL). 
A shift table will be produced for the placebo treatment group to display change from baseline 
eosinophil count ( @220/KL and <220/ KL). A scatterplot comparing historical eosinophil counts 
and baseline eosinophil counts will also be produced for patients with available historical 
eosinophil data. 
[IP_ADDRESS] Serum biomarkers
Serum biomarker samples will be collected at  Week 0, 4, [ADDRESS_746017] samples available.
The results of any investigation will be reported separately in a scientific report or publication.
[IP_ADDRESS] Pharmacogenetics – DNA Sampling 
The pharmacogenetic sample will be collected at Week [ADDRESS_746018] data available. These results w ill be presented outside of the CSR.
[IP_ADDRESS] Mortality rate
The number and percentage of patients who die from any cause w ill be presented by [CONTACT_485642]. Similarly, the number and percentage of respi[INVESTIGATOR_568959].
[IP_ADDRESS] Exploratory objectives in a subset of subjects
Approximately 10% -15% of subjects (54-81 subjects in each arm of the study) will be 
included in a subset study that will be used to assess the exploratory objectives described in Section 1.1.4 .  
The summary statistics and the change from baseline for these exploratory objectives will be 
produced by [CONTACT_266476]:
! FEV
1(L) post-bronchodilator at study center
! Difference between FEV 1 (L) post-bronchodilator change from baseline and FEV 1 
(L) pre-bronchodilator change from baseline 
! Lung volume: total lung capacity (TLC)
! Lung volume: vital capacity (VC)
! Lung volume: residual volume (RV)
! Lung volume: functional residual capacity (FRC)
! Lung volume: inspi[INVESTIGATOR_14008] (IC)
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
54! Diffusion capacity of the lung for carbon monoxide (DL CO)
! [ADDRESS_746019]: distance
! [ADDRESS_746020]: Borg pre- and post-test scores for breathlessness and fatigue
The BODE index ( Celli et al. 2004 ) at Week 0 (Visit 4) will als o be summarised by [CONTACT_485642].
Due to the relatively small number of patients in the sub-study, no formal s tatistical analyses 
will be performed.
[IP_ADDRESS] Sputum biomarkers and differential cell counts
Key baseline characteristics, including subject demographics, baseline disease characteristics, 
cardiovascular history, and baseline efficacy measures will be summarised overall for the sub-
study analysis set and by [CONTACT_569015] ( @3% vs. < 3%).
Sputum differential cell count change from baseline and baseline scaled ratio over time will be 
summarised overall for the sub-study analysis set and by [CONTACT_569016] ( @ 3% vs. < 3%) using descriptive statistics. For the baseline scaled ratio, summary 
statistics will include the geometric mean and coefficient of variation (CV) in addition to the N, median, minimum, maximum and the upper and lower quartiles. The baseline scaled ratio 
is defined as the post-baseline value/baseline value.
Sputum differential cell count absolute values over time (weeks 24 and 56) will be compared 
between the combined benralizumab treatment group (30mg and 100mg groups combined) 
and placebo group using a mixed model for repeated measures analysis with treatment group, 
baseline value, visit and the treatment*visit interaction effects included in the model for patients in the sub-study analysis set overall and by [CONTACT_569015] 
(@3% vs. < 3%). This analysis will be repeated for the baseline scaled ratios on the log-scale, 
with estimates presented as geometric least squares means. Any results equal to zero will be set to 0.[ADDRESS_746021].
The Spearman’s rank correlation coefficient will be calculated to evaluate the correlation 
between baseline blood eosinophil counts (cells/ QL) and baseline sputum eosinophils (%).
Formal comparisons of efficacy endpoints by [CONTACT_569017], however the annual COPD exacerbation rates, pre-
bronchodilator FEV
1change from baseline and SGRQ total score change from baseline will 
be presented graphically by [CONTACT_569015]. 
Additional analyses of sputum biomarkers may be performed and will be presented outside of 
the CSR.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
554.2.9 Safety outcome variables
All safety variables will be summarised using the safety analysis set and data presented 
according to actual treatment received. 
[IP_ADDRESS] Adverse events (AEs) 
Adverse events (AEs) will be summarised separ ately for the on-treatment, on-study, and post-
treatment periods, as defined in Section 3.5.[ADDRESS_746022] 1 AE in any of the following categories: AEs, serious adverse events (SAEs), AEs with outcome of death, and AEs leading to discontinuation of investigational product 
(DAEs). This summary will also be repeated by [CONTACT_569018] (<220/ QL, 
@220/QL) for the on-study, on-treatment, and post-treatment periods.
AEs, AEs with outcome of death, SAEs and DAEs will be summarised by [CONTACT_12360] (SOC) and Preferred Term (PT) assigned to the event by [CONTACT_61132]. For each PT, the 
number and percentage of patients reporting at least 1 occurrence will be presented (ie,multiple occurrences of an AE for a patient will only be counted once). A summary of the 
most common (frequency of @3%) AEs will be presented by [CONTACT_6214]. AEs and SAEs causing 
discontinuation of the study treatment and SAEs causing discontinuation from the study will also be summarised. Presentations for AEs and SAEs will also be repeated for baseline blood 
eosinophil count (<220/ QL, @220/QL) for the on-study, on-treatment, and post-treatment 
periods.
The rate of AEs per person-years at risk, calculated as (number of patients reporting AE)/(total 
period with patients at risk for AE), will also be reported for the on-study and on-treatment 
periods. The total period at risk for each patient  will be the duration of the on-treatment and 
on-study periods as defined in Section 3.5.1 . Rates will be expressed in terms of events per 
100 patient-years.
AEs and SAEs will be summarised by [CONTACT_569019]’s causality assessment 
(related vs. not related) and maximum intensity. If a patient reports multiple occurrences of 
the same AE within the same study period, the ma ximum intensity will be taken as the highest 
recorded maximum intensity (the order being mild, moderate, and severe) and will be summarised for the on-study, on-treatment, and post-treatment periods. Summaries of AEs by 
[CONTACT_1697]’s causality assessment will also be repeated for baseline blood eosinophil count 
(<220/QL, @220/QL) for the on-study and on-treatment periods.
Adverse events of injection site reactions (high level term of administration and injection site) 
and hypersensitivity (standardized MedDRA query of hypersensitivity) will be su mmarised by 
[CONTACT_11702]. The summary of injection site reactions will be summarised by [CONTACT_569020].  The summary of AEs of hypersensitivity (overall 
and causally related to IP) will be repeated for baseline blood eosinophil count (<220/ QL, 
@220/QL) for the on-study, on-treatment, and post-treatment periods.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
56Adjudicated events (major adverse cardiac events (MACE) and malignancies) will be 
summarised by [CONTACT_569021]-treatment and on-study periods and listed.
[IP_ADDRESS] Laboratory data 
All protocol-specified continuous laboratory parameters will be summarised descriptively by 
[CONTACT_569022], together with the corresponding changes from 
baseline. All parameters will be summarised in SI units, with the exception of blood 
eosinophil counts which will be summarised in both SI and conventional units. Results which are reported from the central laboratory in conventional units will be converted to SI units for 
reporting. 
Central laboratory reference ranges will be used for the identification of abnormalities, and a 
shift table will be produced for each laboratory parameter to display low, normal, and high 
values. The shift tables will present baseline and maximum/minimum on-treatment value, as 
applicable for each parameter and will include patients with both baseline and post-baseline data.
Shift plots showing each individual patient’s laboratory value at baseline and at 
maximum/minimum post-baseline will be produced for each continuous laboratory variable. If any laboratory variables show any unusual features (high or low values or a general shift in 
the data points) at other time points, then shift plots of these data may be produced. Data for 
patients who have treatment-emergent changes outside central laboratory reference ranges will be presented.
Maximum post-baseline TBL elevations by [CONTACT_2077]-baseline ALT and AST will be 
presented, expressed as multiples of ULN.  TBL w ill be presented in multiples of the 
following ULN: U1.5, >1.5-2, >2. AST and ALT will be presented in multiples of the 
following ULN: U1, >1-3, >3-5, >5-10, >10.
Maximum post-baseline TBL will be presented (<2 and @[ADDRESS_746023]) and plotted against 
maximum post-baseline ALT (<3, @3-<5, @5-<10, and @[ADDRESS_746024]), expressed as multiples of 
ULN.  This will be repeated to show maximum post-baseline TBL against maximum post-
baseline AST. 
Data for patients with ALT or AST @[ADDRESS_746025], and TBL @[ADDRESS_746026] results 
(including ALP, ALT, AST, TBL, and GGT) over time will also be presented for this subset of patients.
For all patients who meet the biochemical criteria for confirmed Hy’s law, a SAE narrative 
will be produced.
For urinalysis data, a shift table will be generated to present changes from baseline to 
maximum post-baseline value for selected parameters and will include patients with both 
baseline and post-baseline data.  
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
57Descriptive statistics and change from baseline at each visit will be presented for IgE in kU/L 
by [CONTACT_1570].
Any data outside the central laboratory reference ranges will be explicitly noted on the listings 
that are produced.
[IP_ADDRESS] ECGs
A shift table will be produced for each ECG para meter to display normal, abnormal – not 
clinically significant, abnormal – clinically significant, and not done. The shift tables will present baseline and last observation post-baseline value.
In addition, the number and percentage of patien ts with QTcF changes from baseline will be 
presented by [CONTACT_569023] >450 ms, >480 ms and >500 ms and QTcF increase of >30 ms and >[ADDRESS_746027]-dose QTcF change from baseline (with 
reference lines at 30 ms and 60 ms) will be also be produced. 
[IP_ADDRESS] Physical examination
Shift tables (normal, abnormal, not done) of bas eline versus last observation post-baseline 
(normal, abnormal (same as baseline), abnormal (new or aggravated), not done) will be generated, presenting the assessment for each component of the complete physical 
examination separately.
[IP_ADDRESS] Vital signs 
Descriptive statistics and change from baseline for vital signs data will be presented for each 
treatment group by [CONTACT_765].  Baseline to max imum post-baseline and baseline to minimum post-
baseline value shift tables will be generated, as applicable for each parameter and will include patients with both baseline and post-baseline data.
4.2.10 Pharmacokinetic analyses 
The PK analyses will be performed at or under the guidance of [COMPANY_008] Research and 
Development. 
Benralizumab serum concentrations will be summar ised using descriptive statistics at each 
visit by [CONTACT_1570], and will be listed in the CSR.  The population modeling will be 
presented in a separate pharmacometrics report.
4.2.11 Immunogenicity analyses 
Anti-drug antibody (ADA) assessments will be conducted and analysed as per the details in 
Appendix 8.3.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
585. INTERIM ANALYSES
A futility analysis for study efficacy will be performed by [CONTACT_269395] (IDMC). The fut ility analysis will be based on the pooled data of Study 
D3251C00003 and Study D3251C00004 when approximately 15% patients in the @220/KL 
eosinophil stratum have completed the studies. The percentage of patients is based on the total number of patients expected to be recruited in the @220/KL eosinophil stratum of the studies. 
In the futility analysis, a d ecision will be based on the comparison of the futility boundary and 
the estimated exacerbation rate reductions of benralizumab doses vs. placebo in patients with eosinophil counts @220/KL from the negative binomial model as documented for the final 
analysis in Section [IP_ADDRESS] . Futility will be declared if the higher exacerbation rate reduction 
of benralizumab 30mg vs. placebo and benralizumab 100mg vs. placebo is less than 8%. A futility boundary of 8% was chosen based on the operating characteristics of ~55% chance of 
stoppi[INVESTIGATOR_568960] ~2% chance of stoppi[INVESTIGATOR_568961] 30% for both benralizumab doses vs. placebo.
Full details about the fut ility analysis d ecision rules and procedures will be specified in an 
IDMC charter and the charter will also specify the roles and responsibilities of the IDMC members. A firewall will be established to ensure the maintenance of the study blind for the 
sponsor, the investigational site staff and patients. The IDMC charter will also specify the 
timing of analysis and the expected extent of data available at the time of interim analysis. Conducting a fut ility analysis results in power loss thus the sample size calculation in Section 
1.3has accounted for this loss and the study has 90% of power under the powering 
assumptions and the futility boundary of 8%.
6. CHANGES OF ANALYSIS FROM PROTOCOL
The protocol indicated that country would be among the baseline covariates adjusted for in 
formal statistical models. Based on small sample sizes within certain countries and 
consistency with the two Phase [ADDRESS_746028]-order autoregressive, compound symmetric, 
variance components. If the procedure doesn’t converge, the next covariance matrix will be 
used in the order.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
59Exacerbations of Chronic Pulmonary Disease Tool – Respi[INVESTIGATOR_208466] (E-RS) was 
renamed to Evaluating Respi[INVESTIGATOR_568940] (E-
RS: COPD) after it was qualified as an exploratory endpoint (Evidera, 2016). The score range 
for E-RS: COPD for chest symptoms is correctly portrayed in SAP as 0-12 per the E-RS Manual (Evidera, 2016). 
To align with actual ePRO setup, the proportion of nights with awakenings due to respi[INVESTIGATOR_568962].
Additional sub-study analysis set was added for sub-study patients as well as corresponding 
sputum analyses.
Adverse events will also be summarised using the on-study period (in addition to pre-planned 
on-treatment and post-treatment periods).
7. REFERENCES
Burman et al [ADDRESS_746029]. Med. 2009; 28:739–761.
Celli et al. 2004
Celli B.R. et al. The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity 
Index in Chronic Obstructive Pulmonary Disease. The New England Journal of Medicine. 
350;10.
Divo et al. 2012
Divo M, Cote C et al.  Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease.  American Journal of Respi[INVESTIGATOR_568963] 186: 2012
Evidera, Inc. 2014
Evidera, Inc. The Exacerbations of Chronic Pulmonary Disease Tool (EXACT) Patient-Reported Outcome (PRO) USER MANUAL (Version 7.0).
Evidera, Inc. 2016
Evidera, Inc. Evaluating Respi[INVESTIGATOR_208466] (E-RS™) in COPD (E-RS™: COPD) USER 
MANUAL (Version 5.0). Bethesda, MD: Evidera; March 2016
.
Friede and Schmidli 2010
Friede T, Schmidli H. Blinded Sample Size Reestimation with Negative Binomial Counts in 
Superiority and Non-inferiority Trials. Methods of Information in Medicine. 2010; 49(6): 618-
624.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
60GOLD 2014
Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative
for Chronic Obstructive Lung Disease (GOLD) 2014. Available from:
http://www.goldcopd.org.
Hochberg 1988
Hochberg, Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988. 75; 800-2.
Holm [ADDRESS_746030] George’s Respi[INVESTIGATOR_6015]. Respir Med. 1991; [ADDRESS_746031] B:25-31.
Jones et al. [ADDRESS_746032]. Eur Respir J 2009, 34: 648–654.
Jones et al. [ADDRESS_746033] 2011; 139(6):1388–1394.
Leidy et al. 2011
Leidy NK, Wilcox TK, Jones PW, et al. Standardizing measurement of chronic obstructive 
pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am J 
Respir Crit Care  Med 2011;  183(3):323–329.
Mahler et al. 1984
Mahler DA, Weinberg DH, Wells CK, Feinstein AR.; The measurement of dyspnea: contents, inter-observer agreement, and physiologic correlates of two new clinical indexes, Chest 1984; 
85:751–758.
Mahler et al. 2005
Mahler DA, Witek Jr TJ.; The MCID of the transition dyspnea index is a total score of one 
unit., COPD, 2005; 2: 99-103.
Sexton et al. 2010
Sexton C, Notte S, Murray L, Leidy NK. PRO evidence dossier to support the use of the E-RS to evaluate respi[INVESTIGATOR_568964]. United BioSource Corporation; Bethesda, MD: May 2010.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
61Sexton et al. 2011
Sexton C, Leidy NK, Notte SM, et al. Quantifying the severity of respi[INVESTIGATOR_568965]: reliability and validity of a patient diary. Poster presented at the American Thoracic 
Society International Meeting; May 2011: Denver, CO.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
628. APPENDIX
8.1 Accounting for missing data
Accounting for missing data for recurrent events (exacerbation rate endpoint)
In this study some patients droppi[INVESTIGATOR_568966].  
The amount of missing data is minimized in this study as patients are allowed in the protocol 
to switch to an alternative treatment or treatments after they discontinue from randomised treatment and are encouraged to complete visits until they withdraw from the study.   
This section summarises how we will describe the pattern of and reasons for missing data 
from the study.  It will also describe how we plan to account for missing data, including both the primary and sensitivity analyses to assess the robustness of the treatment effect under 
different underlying assumptions to account for missing data.
Missing data descriptions
Tabular summaries for the percentage of patients by [CONTACT_569024].  The time to discontinuation of randomised treatment and withdrawal from the study will be 
presented using Kaplan Meier plots (overall and split by [CONTACT_569025]/not treatment 
related reason for discontinuation, as defined in Tables 1 and 2).  Dependent on these outputs 
additional exploratory analyses may be produced as deemed necessary to further understand 
the pattern of missing data.
Primary analysis under the Treatment Policy Estimand using the Missing at Random (MAR) 
assumption
The primary analysis is under the treatment policy estimand which allows for differences in 
outcomes over the entire study treatment period to reflect the effect of initially assigned randomised treatment as well as if subsequent treatments are taken.  This primary analysis 
includes all data until patients withdraw from the st udy regardless of if they discontinue from 
randomised treatment.  The primary analysis uses the negative binomial regression model with (logarithm of) the observation period as an offset term and assumes that missing data is 
missing at random (MAR) and is a direct likelihood approach (DL). 
Sensitivity analyses under the Treatment Policy Estimand using both MAR and MNAR 
assumptions
To examine the sensitivity of the results of  the primary analysis to departures from the 
underlying assumptions, additional analyses will be performed using controlled multiple imputation method introduced in [1] and further developed at [COMPANY_008] [2,3] which allows 
for different underlying assumptions to be used.  As with the pr imary analysis the sensitivity 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.[ADDRESS_746034]-withdrawal counts and observed prior-
withdrawal counts based on various assumptions.
(1)
Here 
 is number of counts before withdrawal from the study, 
 is number of counts after 
withdrawal from the study, 
 is the dispersion parameter and which is assumed to be the 
same for different treatment arms, j denotes the treatment arm and i denotes the subject 
identifier. Furthermore
(2)
where 
 is the negative binomial distribution (NBD) rate parameter before withdrawal from 
the study, and 
 is the rate parameter after withdrawal from the study as determined based 
on various assumptions. 
The imputed number of exacerbations that would have been seen is then combined with the 
observed exacerbations and data is analysed using the primary analysis methodology (DL). 
This analysis is repeated multiple times and the results combined using Rubin’s formulae [7, 
8].
The following default assumptions that will be used to impute the missing data who withdraw 
early from the study are as follows:
a) MAR: Missing counts in each arm are imputed assuming the expected event rate within 
that arm. 
b) Dropout Reason-based Multiple Imputation (DRMI): Missing counts will be imputed 
differently depending on the reason for dropout; counts for patients in the benralizumab arms who dropped out for a treatment related reason are imputed based on the expected 
event rate in the placebo arm, whereas the remaining patients who have dropped out are 
imputed assuming MAR. Treatment related reasons include (1) AEs, (2) Death, (3) 
Statistical Analysis Plan 
Study Code D3251C00003
Edition Number 3.0
Date 23April 2018
64development of study specified reasons to stop active treatments, and (4) severe non-
compliance of protocol.
Some reasons for withdrawal are clearer to determine as treatment related ( Adverse Events, 
Death, Development of study-specific discontinuation criteria ) or non-treatment related 
(Subject lost to follow up, eligibility criteria not fulfilled ).  Other reasons are less clear such as 
severe non-compliance of protocol, subject decision and ‘Other’; a review of each patient who 
withdraws from the study will therefore be carried out prior to unblinding the study. The review will include assessment of the reason for discontinuation of randomised treatment for 
those patients who discontinued randomised treatment and then withdrew from the study and 
also free text for when the reason for withdrawal or discontinuation of randomised treatment is subject decision or other. Based on this review the default assumptions for DRMI as 
described in b) and Table [ADDRESS_746035] of these patients and the assumptions 
made under DRMI will be documented prior to unblinding of the study. 
A summary of reasons for patients withdrawing from the benralizumab treatment arm and the 
corresponding treatment arm used to calculate the imputation exacerbation rate under MAR
and DRMI is given in Table 1 .
Table 1
Reason for withdrawal MAR DRMI
Adverse Event Benralizumab Placebo
Development of study-specific 
discontinuation criteria*Benralizumab Placebo
Death Benralizumab Placebo
Severe non-compliance to protocol Benralizumab PlaceboEligibility criteria not fulfilled Benralizumab BenralizumabSubject lost to follow up Benralizumab Benralizumab
Subject decision Benralizumab Based on review prior to 
study unblinding
Other Benralizumab Based on review prior to 
study unblinding
Note all patients on exacerbation rate in the placebo arm are imputed using the placebo arm rate
*Development of study-specific discontinuation criteria are based on the following:  anaphylactic reaction to the 
IP requiring administration of epi[INVESTIGATOR_238], development of helminth parasitic infestations requiring 
hospi[INVESTIGATOR_059], [ADDRESS_746036] case assumptions about missing data.  The MAR multiple 
imputation approach is expected to correspond clos ely to the primary analysis, and is included 
to allow for comparisons with MNAR assumptions (specifically methods b and c) using the same multiple imputation methodology.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
65The dropout reason-based multiple imputation (DRMI) approach was selected as the most 
conservative approach based on the fact that placebo patients are receiving standard of care 
and are not expected to change to a substantially more effective treatment after withdrawing 
from study or study treatment. For patients receiving benralizumab who withdraw from the study due to treatment related reasons it is  assumed that at worst they would be on the 
standard of care treatment, ie, the placebo arm.  For patients receiving benralizumab who 
withdraw from the study due to non-treatment re lated reasons it seems reasonable to assume 
they would be similar to those patients who complete treatment.
On-Treatment Analyses (Effectiveness estimand) 
In addition primary and sensitivity analyses described previously, an alternative estimand will 
be estimated using only the on initial randomised treatment data:
! Effectiveness estimand with assumed loss of effect post discontinuation of 
benralizumab: This will be estimated using the DRMI controlled imputation approaches including only data from patients whilst on treatment.
Therefore the primary analyses and sensitivity analyses will be repeated including only data 
from patients whilst being on initial randomised treatment, ie, excluding data once patients 
discontinue from randomised treatment.    
A summary of reasons for patients withdrawing from the benralizumab treatment arm and the 
corresponding treatment arm used to calculate the imputation exacerbation rate under MAR 
and DRMI are given in Table [ADDRESS_746037] of these patients and the assumptions made under DRMI will be documented prior to unblinding of the study.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0
Date 23April 2018
66Table 2
Reason for discontinuation of randomised 
treatmentMAR DRMI
Adverse Event Benralizumab Placebo
Development of study-specific 
discontinuation criteria*Benralizumab Placebo
Severe non-compliance to protocol Benralizumab Placebo
Subject lost to follow up Benralizumab Benralizumab
Subject decision Benralizumab Based on review prior to 
study unblinding
Other Benralizumab Based on review prior to 
study unblinding
Note all patients on exacerbation rate in the placebo arm are imputed using the placebo arm rate
*Development of study-specific discontinuation criteria are based on the following:  anaphylactic reaction to the IP requiring administration of epi[INVESTIGATOR_238], development of helminth parasitic infestations requiring hospi[INVESTIGATOR_059], 2 consecutive doses of IP missed or more than 2 scheduled doses of IP are missed during course 
of the study, a COPD-related event requiring mechanical ventilation.
Using on treatment data is easier to interpret as it is not impacted by [CONTACT_569026].  Sensitivity 
analyses using the effectiveness estimand under the DRMI allow for alternative assumptions 
to be made based on reasons for discontinuation. 
Overall summary of analyses to account for missing data
A summary of the different analyses to be carried out under different estimands and 
assumptions are described in Table 3 .
67Table 3
Treatment Policy Estimand On-Treatment Analyses 
(Effectiveness estimand)
On-treatment + post-discontinuation of randomised 
treatmentOn-treatment
Population Treatment policy 
(MAR)Treatment policy 
(MNAR)Treatment policy 
(MNAR)
Estimand DL MAR DRMI DRMI
Exacerbation rate for 
imputation in Benra arm
bNo explicit 
imputationaBenra for all reasons for 
withdrawal assumed to be on BenraPlacebo rate for AEs, 
Death, development of 
study specified reasons to stop active treatments and Severe non-compliance to protocol assumed to be on, otherwise Benra or based on review prior to study unblindingPlacebo rate for AEs, 
Death, development of 
study specified reasons to stop active treatments and Severe non-compliance to protocol assumed to be on, 
otherwise Benra or based 
on review prior to study unblinding
Default definition  
for
and
based on 
formula (2)c.
For all treatment arms 
j=B and P
 for reasons  
above otherwise
for reasons  above otherwise
aImplicitly assumes unobserved rate the same as observed 
bAll patients on exacerbation rate in the placebo arm are imputed using the placebo arm rate (ie, 
 )
cNote can be over written by [CONTACT_569027]
B  Benralizumab 30mg or 100mg; P  Placebo
Forest plots will be used to show the primary analysis results along with the missing data 
sensitivity and alternative estimand analysis results.
It is noted that if the primary analysis is statistic ally significant, it is not necessarily expected 
that all sensitivity analyses will also give statistica lly significant results. If the results of the 
sensitivity analyses provide reasonably similar estimates of the treatment effect to the primary 
analysis, this will be interpreted as providing assurance that neither the lost information nor the mechanisms which cause the data to be missing have an important effect on primary 
analysis conclusions. Based on these outputs and the drug’s mechanism of action, the 
plausibility of the assumptions we make about missing data in the different analyses will be considered and described in the clinical study report. 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0Date 23 April 2018
68Accounting for missing data for continuous endpoints (FEV1 and SGRQ total score)
Missing data descriptions
In addition to the tables and figures suggested above, plots of change from baseline vs time, 
by [CONTACT_569028] (eg, completers vs non-completers, split by [CONTACT_569029]/or split 
by [CONTACT_569030]) will also be produced.
Primary analysis under the Treatment Policy Estimand using the MAR assumption
As for the primary variable, the primary analysis of the FEV1 and SGRQ total score key 
secondary endpoints includes all data captured during the trial and is therefore considered to 
be under the treatment policy estimand. The Mixed Model Repeated Measures model (MMRM) used is a DL approach which is valid under the MAR assumption. 
Sensitivity analysis under the Treatment Policy Estimand using MNAR assumptions
Sensitivity analyses of the repeated measures analyses will be performed for the FEV1 and 
SGRQ total score using controlled sequential multiple imputation methods based on pattern 
mixture models, as described in [5]. 
The method is analogous to the multiple impu tation of exacerbation even ts and the imputation 
process consists of a sequence of MI steps, where each step is intended to impute missing 
values at [ADDRESS_746038] correlations  with future (unobserved) visits similar to 
subjects in the placebo arm. As for the exacerbation events, this allows us to assess various 
deviations from the MAR assumption.
The assumptions that will be used to impute the missing data who withdraw early are as 
follows:
(a) MAR: Assumes that the trajectory for patients who dropped out in each arm is 
similar to those observed in their own treatment arm
(b) DRMI: Assumes that the trajectory for patients in the benralizumab arms who 
dropped out for a treatment related reasons (according to the same classification as 
for the DRMI analysis of the primary endpoint) is similar to that of the placebo subjects, whereas the remaining patients who has dropped out are imputed assuming 
MAR.
Approach b) can be considered more conservative than the approach for the primary analysis 
because the assumptions mean that as soon as subjects withdraw for a treatment related 
reason, they begin to worsen immediately. 
The MNAR imputation is achieved by [CONTACT_569031]. Imputation will be done in 2 steps, the non-monotone (intermediate) missing 
FEV1 values will be imputed first (Markov chain Monte Carlo (MCMC) method is used to 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0Date 23 April 2018
69partially impute the data using SAS PROC MI) and then the missing value at each visit will be 
imputed using a sequential regression method (using MONOTONE REG option of SAS 
PROC MI). 
For example, to impute missing values at time t for subjects in the benralizumab arms, that 
dropped out due to an AE, include only placebo observations up to and including time t, plus 
observations from subjects in the benralizumab arms, that dropped out due to an AE, up to and including time t-1. This is done for each visit, [ADDRESS_746039] imputed. Placebo missing observations and benralizumab observations that are not 
missing due to AEs are imputed assuming missing at random (MAR) and follow the pattern of observed placebo observations in each treatment arm respectively. 100 imputations will be 
carried out, and a seed of 784088 will be used for the monotone imputation step and a seed of 
409345 will be used for the sequential regression imputation step. The analysis of each of the imputed dataset will be as described for the primary analysis in Section [IP_ADDRESS] and these will 
be combined using SAS procedure PROC MIANALYSE. 
To avoid possible convergence issues when fitting MMRM models to [ADDRESS_746040] imputation where the model 
converges will be used as the starting values to fit the models for all imputed datasets.
On-Treatment Analyses (Efficacy and Effectiveness estimands) 
Analogously to the approach for the primary endpoi nt, efficacy and effe ctiveness estimands 
will be estimated using on-treatment data and the methods described above. 
Results for continuous endpoints will be presented as per the recurrent event sensitivity 
analyses.
References
1. Keene ON, Roger JH, Hartley BF, Kenward MG. Missing data sensitivity analysis 
for recurrent event data using controlled imputation. Pharmaceutical Statistics 2014, 
13 258–264.
2. Wan R, Hirsch I, Gottlow M, Hollis S, Darilay A, Weissfeld L, [LOCATION_009] L. 
Controlled imputation approach for analyzing missing data in recurrent events due 
to early discontinuations. DIA/FDA Statistics Forum 2015.
3. Gottlow M, Hollis S, Wan R, Hirsch I, Darilay A, Weissfeld L, [LOCATION_009] L. A 
Simulation study of a controlled imputation approach for analyzing missing data in 
recurrent events due to early discontinuations. PSI Annual Conference 2015.
4. The Panel on Handling Missing Data in Clinical Trials; National Research Council. 
The Prevention and Treatment of Missing Data in Clinical Trials. National 
Academies Press, 2010.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0Date 23 April 2018
705. Guideline on Missing Data in Confirmatory Clinical Trials 2 July 2010 
EMA/CPMP/EWP/1776/99 Rev. 1
6. AZ guidance (clinical OPI): Guidance on Minimizing the Loss of Patient Data in 
[COMPANY_008] Clinical Trials, ed 2.0. (LDMS_001_00102309)
7. Fleming, TR. Addressing Missing Data in Clinical Trials. Ann. Intern. Med. 
2011;154:113-117.
8. Ratitch B, O’Kelly M, Tosiello R. Missing data in clinical trials: from clinical 
assumptions to statistical analysis using pattern mixture models. Pharmaceutical 
Statistics 2013; 12: 337-347.
9. Rubin DB. Multiple imputation for nonresponse in surveys. [LOCATION_001]: John Wiley 
& Sons, Inc. 1987.
10. Barnard J, Rubin DB. Small-sample degrees of freedom with multiple imputation. 
Biometrika 1999; 86:948-955.
11. Mallinckrodt CH, Lin Q, Lipkovich I, Molenberghs G. A structured approach to 
choosing estimands and estimators in longitudinal clinical trials. Pharmaceutical Statistics 2012, 11:456–461. 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0Date 23 April 2018
718.2 Partial dates for adverse events and prior/concomitant medication 
Dates missing the day or both the day and month of the year will adhere to the following 
conventions in order to classify treatment-em ergent AEs and to classify prior/concomitant 
medications:
Adverse Events
! The missing day of onset of an AE will be set to:
First day of the month that the event occurred, if the onset YYYY-MM is after 
the YYYY-MM of first study treatment
The day of the first study treatment, if the onset YYYY-MM is the same as 
YYYY-MM of the first study treatment
The date of informed consent, if the onset YYYY-MM is before the 
YYYY-MM of the first treatment.
! The missing day of resolution of an AE will be set to:
The last day of the month of the occ urrence. If the patient died in the same 
month, then set the imputed date as the death date.
! If the onset date of an AE is missing both the day and month, the onset date will be 
set to:
January [ADDRESS_746041] 
study treatment
The date of the first treatment, if the onset year is the same as the year of the 
first study treatment
The date of informed consent, if the onset year is before the year of the first 
treatment
! If the resolution date of an AE or end date of a IP is missing both the day and 
month, the date will be set to:
December 31 of the year of occurrence. If the patient died in the same year, 
then set the imputed date as the death date.
Prior/concomitant medication
! The missing day of start date of a therapy will be set to the first day of the month 
that the event occurred.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0Date 23 April 2018
72! The missing day of end date of a therapy will be set to the last day of the month of 
the occurrence.
! If the start date of a therapy is missing both the day and month, the onset date will 
be set to January 1 of the year of onset.
! If the end date of a therapy is missing both the day and month, the date will be set to 
December 31 of the year of occurrence.
! If the start date of a therapy is null and the end date is not a complete date then the 
start date will be set to the date of the first study visit.
! If the start date of a therapy is null a nd the end date is a complete date
and the end date is after the date of the first study visit then the start date will 
be set to the date of the first study visit.
otherwise the start date will be set to the end date of the therapy.
! If the end date of a therapy is null and the start date is not a complete date then the 
end date will be set to the study end date. 
! If the end date of a therapy is null and the start date is a complete date
and the start date is prior to the study end date then the end date will be set to
the study end date.
otherwise, the end date will be set to the start date of the therapy.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0Date 23 April 2018
738.3 Analysis plan for immunogenicity data
The purpose of this appendix is to provide a general reference for the analysis of anti-drug 
antibody (ADA) data in this study.  The comple te set of presentations described in this 
appendix will be conducted. 
All analyses will be conducted on the safety an alysis set by [CONTACT_569032].  These analyses will also be presented for subjects with baseline blood eosinophils 
@220/KL in the safety analysis set.  All ADA results will be listed. 
Serum samples for ADA assessments will be conducted utilising a tiered approach (screen, 
confirm, titre) and ADA data will be collected at scheduled visits shown in the CSP.  ADA 
result from each sample will be reported as either positive or negative.  If the sample is positive, the ADA titre will be reported as well.  In the event that an ADA sample is collected 
post-IP dose instead of pre-dose (protocol deviation), the post-dose ADA sample will be 
included in listings however will be excluded from all derivations and summaries. In addition, the presence of neutralizing antibody (nAb) will be tested in all ADA-positive 
samples using a ligand-binding assay.  The nA b results will be reported as positive or 
negative. 
For each subject, the following ADA res ponse variables will be evaluated: 
! ADA prevalence; defined as ADA positive at any visit including baseline and/or post-
baseline (also generally referred to as ADA positive)
! ADA incidence; defined as ADA negative at baseline and ADA positive at any post-
baseline visit, or ADA positive at baseline and a boosted ADA post-baseline titre result 
(> 4-fold increase)
! ADA positive at baseline and at least one post-baseline positive assessment
! ADA positive post-baseline only
! ADA positive at baseline only
! ADA persistently positive; defined as ADA negative at baseline and at least [ADDRESS_746042] 16 weeks (112 days) between the 
first and last positive measurement or an ADA positive result at the last available 
assessment
! ADA transiently positive; defined as ADA negative at baseline and at least one post-
baseline ADA positive measurement and not fulfilling the conditions for persistently 
positive
! nAb prevalence; defined as nAb positive at any visit including baseline and/or post-
baseline (also generally referred to as nAb positive)
! nAb incidence; defined as nAb negative at baseline (or ADA negative at baseline) and 
nAb positive at any post-baseline visit. Patients who are ADA negative at baseline are 
included to ensure that all patients who are nAb positive for the first time post-baseline satisfy this definition, given that patients who are ADA negative at baseline would not 
have an nAb result reported
! ADA positive with maximum titre > median of maximum titres
! ADA positive with maximum titre U median of maximum titres
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0Date [ADDRESS_746043]-treatment follow up visit. The proportion of subjects with the responses above will be 
summarized by [CONTACT_1570]. No comparisons or formal hypothesis testing will be conducted.
In ADA positive subjects, the ADA titre at each visit and the maximum titre across the 
different visits will be summarised by [CONTACT_9086] [n, minimum, quartiles (Q1, median and Q3) and maximum].  The maximum titre will be derived based on all ADA titre
results reported up to the time point of interest for each subject.  If a titre result is reported as 
U50 at a specific visit, then the titre for this visit will be imputed as [ADDRESS_746044] will be 
summarised in subjects who are ADA persistently positive with titre Umedian of maximum 
titres and in the subjects who are ADA persistently positive with titre > median of maximum titres.  The median of maximum titres will be calculated based on the maximum titre for each 
ADA positive subject within each treatment group.
A summary of ADA positive subjects who had >[ADDRESS_746045]-
baseline ADA positive result, as well as subjects with >75% decrease in titre from the 
maximum titre (excluding the post-treatment follow-up assessment) will be produced for each 
treatment group.  For a titre change from positive to negative to represent a >75% decrease, the maximum titre must be @200. Patients must have two pos t-baseline positive ADA results.
Demographic and patient characteristics by [CONTACT_569033]; 
ADA positive, ADA negative, ADA persistently positive, and nAb positive. 
ADA results by [CONTACT_569034] a positive ADA result and the ADA titres will be summarised 
at baseline and at all scheduled post-baseline visits by [CONTACT_1570].  
To classify the ADA 
responses at each visit, the ADA result reported within the derived analysis visit window will be 
included in the analyses. The analysis visit windows are defined in Section 2.2.[ADDRESS_746046] of ADA on the primary endpoint (annual COPD exacerbation rate) and two key 
secondary endpoints (change from baseline in pre-BD FEV 1and change from baseline in 
SGRQ total score) will be evaluated in subgroups of ADA positive, ADA negative, ADA 
persistently positive, ADA positive with maximum titre > median of maximum titres, nAb 
positive, and ADA persistently positive and nAb positive. Due to the expected small number of ADA positive subjects in the placebo group, no formal statistical analysis on efficacy 
(benralizumab vs placebo) by [CONTACT_258465] (positive/negative) is planned.  
For annual COPD exacerbation rates, a descriptive summary by [CONTACT_569035].  The maximum 
follow-up time for calculation of the annual COPD exacerbation rate will be as defined in 
Section 3.1. The 95% confidence interval for the treatment group rates will be estimated based 
on the Poisson distribution. For FEV1 and SGRQ total scores, the last non-missing 
observation on or prior to the EOT (Week 56) or IPD visit will be used to calculate arithmetic 
means by [CONTACT_1570], rather than the estimated least squares means estimated from the mixed model for repeated measures (MMRM).
Safety by [CONTACT_569036]-treatment and on-study 
periods by [CONTACT_569037], ADA negative, ADA positive with titre > median of 
maximum titre and ADA persistently positive. Summaries will include adverse events (AEs), 
serious adverse events (SAEs), causally related AEs and SAEs as assessed by [CONTACT_093], and adverse events of hypersensitivity.
Relative risk comparisons between ADA positive versus ADA negative patients for safety 
outcomes are not planned due to the low expected frequency of the potential adverse events (AE) related to the potential risk (at the preferred term level).
Pharmacokinetics by [CONTACT_569038] (positive, 
negative) using the following descriptive st atistics: n, geometric mean, geometric mean 95% 
CI, geometric mean coefficient of variation (CV), arithmetic mean, standard deviation, 
median, minimum and maximum.
Blood eosinophils by [CONTACT_569039], ADA 
negative, ADA positive with titre > median of maximum titres, ADA persistently positive, nAb positive, and both ADA persistently positive and nAb positive using the following 
descriptive statistics: n, mean, standard deviation, median, minimum and maximum.  
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0Date 23 April 2018
768.4 Important protocol deviations
As specified in Section 2.2.1 , important protocol deviations (PDs) are a subset of protocol 
deviations that may significantly impact the completeness, accuracy, and/or reliability of the 
study data or that may significantly affect a subject’s rights, safety, or well-being. The following important PDs will be summarised and listed in the CSR (*indicates an important 
PD which may impact the primary efficacy endpoint): 
A. Eligibility criteria not met (patients incorrectly randomised) – deviation(s) from 
inclusion criteria:
1. Provision of informed consent prior to any study specific procedures.
2. History of moderate to very severe COPD with a post-bronchodilator FEV1/FVC<0.[ADDRESS_746047]-bronchodilator FEV1>20% and U65% of predicted normal value at 
screening (central spi[INVESTIGATOR_568967]).*
3. History of 2 or more moderate COPD exacerbations that required treatment with 
systemic corticosteroids and/or antibiotics, or 1 or more severe COPD exacerbation(s) 
that required hospi[INVESTIGATOR_059] (defined as an inpatient admission @24 hours in the 
hospi[INVESTIGATOR_307], in an observation area, the emergency department or other equivalent 
healthcare facility depending on the c ountry and healthcare system) within 2 to 52 
weeks prior to enrolment. Prior use of antibiotics alone does not qualify as a moderate 
exacerbation unless the antibiotic was specifically prescribed for the treatment of 
worsening COPD symptoms.*
4. mMRC score @1 at Visit 1.*
5. Subjects should have evidence of having been treated with double (ICS/LABA or 
LABA/LAMA) or triple (ICS/LABA/LAMA) therapy for COPD throughout the year 
prior to enrolment (Visit 1). It is acceptable for subjects to have stepped up or stepped 
down during that period of time (from double to triple therapy and vice versa), but 
they have to be consistently treated with locally approved COPD medications and on 
approved doses for at least 2 weeks prior to enrolment (Visit 1). Subjects currently 
receiving background therapy that is not approved for COPD are not eligible for the 
study.*
6. Ability to read, write and use electronic devices.*
7. Blood eosinophils due to subject’s stratification and cap for blood eosinophil levels. 
When any eosinophil cohort (<220/ KL, 220-299/ KL, or @300/KL) is full, subjects in the 
completed cohort will not be randomised and will be withdrawn from the study (see 
CSP Section 3.7.2).*
8. Provision of a signed and dated written informed consent for the pharmacogenetic 
sample and analysis. If a subject declines to participate in the pharmacogenetic 
research, there will be no consequence or loss of benefit to the subject. The subject 
will not be excluded from the other aspects of the study described in the CSP, as long 
as they consent to participate in the study.
B. Eligibility criteria not met (patients incorrectly randomised) – deviation(s) from 
exclusion criteria:
1. Clinically important pulmonary disease other than COPD (e.g. active lung infection, 
clinically significant bronchiectasis, pulmonary fibrosis, cystic fibrosis, 
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0Date 23 April 2018
77hypovent ilation s yndrome associated with obesity, lung cancer, alpha 1 anti-trypsin 
deficiency and primary ciliary dyskinesia) or another diagnosed pulmonary or 
systemic disease that is associated with elevated peripheral eosinophil counts (e.g. 
allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, 
hypereosinophilic syndrome) and/ or radiological findings suggestive of a respi[INVESTIGATOR_568968]’s respi[INVESTIGATOR_1856].*
2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, 
renal, neurological, musculoskeletal, infe ctious, endocrine, metabolic, haematological, 
psychiatric, or major physical impairment that is not stable in the opi[INVESTIGATOR_286098]/or could:
-Affect the safety of the subject throughout the study
-Influence the findings of the study or their interpretation
-Impede the subject’s ability to complete the entire duration of study
Subjects who have epi[INVESTIGATOR_244797] a stable dose of medication for 30 days prior to 
Visit 4.*
3. Unstable ischemic heart disease, arrhythmia, cardiomyopathy, heart failure, renal 
failure, uncontrolled hypertension as defined by [CONTACT_737], or any other relevant 
cardiovascular disorder as judged by [CONTACT_569040]/run-in period that in Investigator’s judgement may put 
the patient at risk or negatively affect the outcome of the study.*
4. Pregnant, breastfeeding, or lactating women.
5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level @1.5 times 
the upper limit of normal (ULN) confirmed by [CONTACT_476657].
6. Risk factors for pneumonia (including, but not limited to: immunosuppression, 
neurological disorder with increased risk of aspi[INVESTIGATOR_1516]).*
7. Known history of allergy or reaction to any component of the investigational product 
formulation.
8. History of anaphylaxis to any other biologic therapy.
9. Long term oxygen therapy (LTOT) with signs and/or symptoms of cor pulmonale 
and/or right ventricular failure. Subjects receiving long term treatment with oxygen > 
4.0 liters/minute (L/min). While breathing supplemental oxygen, subjects should
demonstrate an oxyhemoglobin saturation @89 %. In order to be admitted to the trial 
subjects on LTOT have to be ambulatory and be able to attend clinic visits.*
10. Use of any non-invasive positive pressure ventilation device (NIPPV). Note: Subjects 
using continuous positive airway pressure (CPAP) or bilevel positive airway pressure 
(BiPAP) for Sleep Apnea Syndrome are allowed in the study.*
11. Any clinically significant abnormal findings in physical examination, vital signs, 
haematology, clinical chemistry, or urinaly sis during screening/run-in period, which, 
in the opi[INVESTIGATOR_689], may put the subject at risk because of his/her 
participation in the study, or may influence the results of the study, or the subject’s 
ability to comp lete entire duration of the study.
12. Fever > 37.8°C (100°F) measured using the tympanic temperature (or equivalent 
oral/rectal/axillary temperature) at Visit 4.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0Date 23 April 2018
7813. Use of immunosuppressive medication, including rectal corticosteroids and systemic 
steroids within 2 weeks prior to enro lment (Visit 1) and/or during the enrolment and 
screening/run-in period.*
14. Receipt of any investigational non-biologic product within 30 days or 5 half-lives prior 
to Visit 1.
15. Receipt of any marketed (e.g. omalizumab) or  any other monoclonal or polyclonal 
antibody therapy (e.g. gamma globulin) taken for any reason within 6 months or 5 
half-lives prior to Visit 1, whichever is longer.*
16. Receipt of live attenuated vaccines [ADDRESS_746048] any of the following:
- A history of known immunodeficiency dis order including a positive test for human 
immunodeficiency virus, HIV-[ADDRESS_746049] year, which may compromise the 
study data interpretation as j udged by [CONTACT_569041].*
20. Malignancy, current or within the past [ADDRESS_746050] evidence of 
active tuberculosis (TB). Subjects with a recent (within 2 years) first-time or
newly positive purified protein derivative ([COMPANY_003]) test or Quantiferon test need to 
complete an appropriate course of treatment before being considered for enrolment.
Evaluation will be according to the local standard of care and may consist of history 
and physical examinations, chest x-ray, and/or TB test as determined by [CONTACT_259138].*
22. Subjects with lung volume reduction surgery within the 6 months prior to Visit 1.
Subjects with history of partial or total lung resection (single lobe or segmentectomy is 
acceptable).*
23. Asthma as a primary or main diagnosis according to the Global Initiative for Asthma 
(GINA) guidelines (GINA 2011) or other accepted guidelines. Subjects with a past 
medical history of asthma (e.g. childhood or adolescence) may be included.*
24. Previous treatment with benralizumab (MEDI-563).*
25. Previous allogeneic bone marrow transplant.*
26. Non-leukocyte depleted whole blood transfusion within 120 days of the genetic sample 
collection.
C. Deviations from IP discontinuation procedures:
1. Subject developed criteria for discontinuation of IP (as defined in the CSP Section 3.6) 
but continued IP treatment without consultation with AZ Study Phys ician.
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0Date 23 April 2018
79D. Received prohibited/ restricted concomitant medication:
1. Systemic corticosteroids (tablets, suspension or injections) administered outside of 
COPD exacerbation event.*
2. Antibiotics taken for prevention of COPD exacerbation.*
3. Use of any of the following medications:*
• Roflumilast (Daxas, Daliresp) after Visit 1 and during the study.
• Any monoclonal antibody (e.g. omalizumab, denosumab) or polyclonal antibody 
(e.g. gamma globulin) within 6 months prior to Visit 1 and during the study.
• Allergen immunotherapy within 90 days prior to Visit 1 and during the study.
• Live attenuated vaccines within [ADDRESS_746051] dose of IP.
• Potent Cytochrome P (CYP) 3A4 inhibitors (if used for >4 weeks)
E. Deviations from requirements on background double/triple COPD therapy:
1. Patient not on double/triple COPD medications for >4 weeks during the treatment 
period (e.g. interruptions and/or step-down to  mono therapy). Note: any deviations 
from Inclusion criteria #[ADDRESS_746052] be coded as deviation 
from eligibility criteria.*
F. Deviations from visit schedule and study procedures:
1. Multiple phone visits / phone follow-up visits (more than 2) missed during the 
treatment phase/ follow-up.*
2. COPD exacerbation not assessed and reported as per protocol.*
3. Central spi[INVESTIGATOR_568969]2/Visit4:
• assessment not performed
• unacceptable post-PD spi[INVESTIGATOR_568970] 2 not consulted with Study Physicians and 
not repeated
Other important/ repeated violations in spi[INVESTIGATOR_1891] (to be consulted with 
Study physicians)*
4. Central spi[INVESTIGATOR_568971]/ repeated violations in 
spi[INVESTIGATOR_568972] ( @ 3) visits after randomization.*
5. Any safety assessment (ECG, physical examination, vital signs, safety lab tests) not 
performed at screening, baseline and/or at multiple ( @ 3) visits after randomization.
6. Pregnancy test not done prior to randomization and/or at @ 2 visits after randomization.
7. Central blood eosinophil testing not done/ results not received prior to randomization.*
8. Any other study procedures not performed or incorrectly performed at multiple ( @ 3) 
visits for the same subject.*
G. IP management and treatment blinding:
1. IP is not administered according to the protocol*
• Incorrect route of administration
• Incorrect dose 
• IP administered prior to completion of all visit procedures
Statistical Analysis Plan 
Study Code  D3251C00003
Edition Number 3.0Date 23 April 2018
802. IP administered in a presence of condition(s) contraindicating dosing.
3. Patient not observed for a minimum of [ADDRESS_746053] randomised treatment (wrong kit ID) administered.*
5. IP administered with interval between doses <3 weeks or >10 weeks.*
6. Use of expi[INVESTIGATOR_568973]/ syringe.*
7. Use of IP with temperature excursi on without any approval from Supply Chain 
manager (not given either prior to or after IP administration to subject).*
H. Other: Important PDs that do not fall into any above categories. Details of these 
important PDs will be described in the CSR.*